Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  09-Jan-2019A Phase 3, Multicenter, Randomized, Double-blind, Active
Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate 
the Safety, Tolerability, and Immunogenicity of V114 in Healthy 
Adults 50 Years of Age or Older (PNEU-TRUE)
PRODUCT: V114  1
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Title Page
THIS PROTOCOL AND ALL OF THE INFORMATION RELATING TO IT ARE 
CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & 
DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. (MSD).
Protocol Title: A Phase 3, Multicenter, Randomized, Double -blind, Active 
Comparator -controlled ,Lot-to-Lot Consistency  Study  to Evaluate the Safety , Tolerability , 
and I mmunogenicity  of V114 in Healthy  Adults 50 Years of Age or Older (PNEU -TRUE)
Protocol Number: 020-00
Compound Number: V114
Sponsor Name:
Merck Sharp & Dohme Corp., a subsidiary  of Merck & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One Merck Drive
P.O. Box 100
Whitehouse Station, New Jersey , 08889 -0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND
EudraCT14977
2018 -004266 -33
Approval Date: 09 January  2019 
  054D4P 
  05KG6X
PRODUCT: V114  2
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Sponsor Signatory
Typed Name:
Title:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide b y all provisions of this protocol.
Typed Name:
Title:Date 
  054D4P 
  05KG6X
PRODUCT: V114  3
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
DOCUMENT HISTORY
Document Date of Issue Overall Rationale
Original Protocol 09-JAN-2019 Not applicable 
  054D4P 
  05KG6X
PRODUCT: V114  4
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
1 PROTOCOL SUMMARY ............................................................................................ 11
1.1 Synopsis ................................................................................................................. 11
1.2 Schema .................................................................................................................. 14
1.3 Schedule of Activities (SoA) ................................................................................ 15
2 INTRODUCTION .......................................................................................................... 17
2.1 Study Rationale .................................................................................................... 17
2.2 Background .......................................................................................................... 17
2.2.1 V114 and Pneumococcal Disease ................................................................ 17
2.2.2 Preclinical and Clinical Studies ................................................................... 18
2.2.3 Information on Other Study -Related Therapy ............................................. 18
2.3 Benefit/Risk Assessment ...................................................................................... 19
3 HYPOTHESES, OBJECTIV ES, AND ENDPOINTS ................................................ 19
4 STUDY DESIGN ............................................................................................................ 21
4.1 Overall Design ...................................................................................................... 21
4.2 Scientific Rationale for Study Design ................................................................ .21
4.2.1 Rationale for Endpoints ............................................................................... 22
4.2.1.1 Immunogenicit y Endpoints ................................................................ 22
4.2.1.2 Safety  Endpoints ................................................................................ 23
4.2.1.3 Pharmacokinetic Endpoints ............................................................... 23
4.2.1.4 Pharmacod ynamic Endpoints ............................................................. 23
4.2.1.5 Future Biomedical Research .............................................................. 23
4.2.2 Rationale for the Use of Comparator/Placebo ............................................. 23
4.3 Justification for Dose ........................................................................................... 24
4.4 Beginning and End of Study Definition ............................................................. 24
4.4.1 Clinical C riteria for Early Study Termination ............................................. 24
5 STUDY POPULATION ................................................................................................ 24
5.1 Inclusion Criteria ................................................................................................ .24
5.2 Exclusion Criteria ................................................................................................ 25
5.3 Lifestyle Considerations ...................................................................................... 27
5.4 Screen Failures ..................................................................................................... 27
5.5 Participant Replacement Strategy ...................................................................... 27
6 STUDY INTERVENTION ............................................................................................ 27
6.1 Study Intervention(s) Administered ................................................................... 27 
  054D4P 
  05KG6X
PRODUCT: V114  5
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
6.2 Preparation/Handling/Storage/Accountability ................................................. 29
6.2.1 Dose Preparation .......................................................................................... 29
6.2.2 Handling, Storage, and Accountability ........................................................ 29
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. 30
6.3.1 Intervention Assignment.............................................................................. 30
6.3.2 Stratification ................................................................................................ .30
6.3.3 Blinding ........................................................................................................ 30
6.4 Study Intervention Compliance .......................................................................... 31
6.5 Concomitant Therapy .......................................................................................... 31
6.5.1 Rescue Medications and Supportive Care ................................................... 32
6.6 Dose Modification (Escalation/Titration/Other) ............................................... 32
6.7 Intervention After the End of the Study ............................................................ 32
6.8 Clinical Supplies Disclosure ................................................................................ 32
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
WITHDRAWAL ............................................................................................................ 32
7.1 Discontinuation of Study Intervention ............................................................... 32
7.2 Participant Withdrawal From the Study ........................................................... 32
7.3 Lost to Follow -up................................................................................................ .33
8 STUDY ASSESSMENTS AN D PROCEDURES ........................................................ 33
8.1 Administrative and General Procedures ........................................................... 34
8.1.1 Informed Consent ......................................................................................... 34
8.1.1.1 General Informed Consent ................................
................................ .34
8.1.1.2 Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 35
8.1.2 Inclusion/Exclusion Criteria ........................................................................ 35
8.1.3 Participant Identification Card ..................................................................... 35
8.1.4 Medical History ........................................................................................... 35
8.1.5 Prior and Concomitant Medications Review ............................................... 36
8.1.5.1 Prior Medications ............................................................................... 36
8.1.5.2 Concomitant Medications .................................................................. 36
8.1.6 Assignment of Screening Number ............................................................... 36
8.1.7 Assignment of Treatment/Randomization Number ..................................... 36
8.1.8 Study  Intervention Administration .............................................................. 36
8.1.8.1 Timing of Dose Administration ......................................................... 37
8.1.9 Electronic Vaccination Report Card (eVRC) .............................................. 37
8.1.10 Telephone Contact Questionnaire ................................................................ 38
8.1.11 Discontinuation and Withdrawal ................................................................ .38
8.1.11.1 Withdrawal From Future Biomedical Research ................................ 38 
  054D4P 
  05KG6X
PRODUCT: V114  6
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
8.1.12 Participant Blinding/Unblinding .................................................................. 39
8.1.13 Calibration of Equipment ............................................................................. 39
8.2 Immunogenicity Assessments ............................................................................. 40
8.2.1 Multiplex Opsonophagocytic Assay (MOPA) ............................................. 40
8.2.2 Electrochemiluminescence (ECL) ............................................................... 40
8.3 Safety Assessments ............................................................................................... 41
8.3.1 Physical Examination ................................................................................... 41
8.3.2 Pregnancy  Test ............................................................................................. 41
8.3.3 Body Temperature Measurement ................................................................ .41
8.3.4 Safety  Assessments and Use of the eVRC ................................................... 42
8.3.5 Clinical L aboratory  Assessments ................................................................ .42
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Reportable Safety Events .................................................................................... 42
8.4.1 Time Period and Frequency  for Collecting AE, SAE, and Other 
Reportable Safet y Event Information .......................................................... 43
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safet y Events ......44
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety  Event Information ...45
8.4.4 Regulatory  Reporting Requirements for SAE ............................................. 45
8.4.5 Pregnancy  and Exposure During Breastfeeding .......................................... 45
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ 45
8.4.7 Events of Clinical I nterest (ECI s)................................................................ 46
8.5 Treatm ent of Overdose ........................................................................................ 46
8.6 Pharmacokinetics................................................................................................ .46
8.7 Pharmacodynamics .............................................................................................. 46
8.8 Future Biomedical Research Sample Collection ............................................... 46
8.9 Medical Resource Utilization and Health Economics ....................................... 46
8.10 Visit Requirements ............................................................................................... 46
8.10.1 Screening ...................................................................................................... 46
8.10.2 Treatment Period/Vaccination Visit ............................................................ 47
9 STATISTICAL ANALYSIS PLAN ............................................................................. 47
9.1 Statistical Analysis Plan Summary..................................................................... 47
9.2 Responsibility for Analyses/In -house Blinding ................................................. 48
9.3 Hypotheses/Estimation ........................................................................................ 49
9.4 Analysis Endpoints ............................................................................................... 49
9.4.1 Immunogenicit y Endpoints .......................................................................... 49
9.4.2 Safety  Endpoints .......................................................................................... 49
9.5 Analysis Populations ............................................................................................ 50 
  054D4P 
  05KG6X
PRODUCT: V114  7
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
9.5.1 Immunogenicit y Analysis Populations ........................................................ 50
9.5.2 Safety Anal ysis Populations ........................................................................ 50
9.6 Statistical Methods ............................................................................................... 51
9.6.1 Statistical Methods for Immunogenicit y Anal yses...................................... 51
9.6.2 Statistical Methods for Safety Anal yses...................................................... 53
9.6.3 Demographic and Baseline Characteristics and Other Anal ysis.................. 55
9.7 Interim Analyses .................................................................................................. 56
9.8 Multiplicity ........................................................................................................... 56
9.9 Sample Size and Power Calculations ................................................................ .56
9.9.1 Sample Size and Power for I mmunogenicity  Analy ses............................... 56
9.9.2 Sample Size and Power for Safet y Anal yses............................................... 57
9.10 Subgroup Analyses ............................................................................................... 58
9.11 Compliance (Medication Adherence) ................................................................ .59
9.12 Extent of Exposure ............................................................................................... 59
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS ..................................................................................................... 60
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........ 60
10.1.1 Code of Conduct for Clinical Trials ............................................................. 60
10.1.2 Financial Disclosure ..................................................................................... 62
10.1.3 Data Protection ............................................................................................. 62
10.1.3.1 Confidentiality  of Data ...................................................................... 63
10.1.3.2 Confidentiality  of Participant Records ............................................... 63
10.1.3.3 Confidentiality  of IRB/IEC I nformation ............................................ 63
10.1.4 Committees Structur e................................................................................... 63
10.1.4.1 Scientific Advisory  Committee .......................................................... 63
10.1.4.2 Executive Oversight Committee ........................................................ 63
10.1.4.3 External Data Monitoring Committee ............................................... 64
10.1.5 Publication Policy ........................................................................................ 64
10.1.6 Compliance with Study  Registration and Results Posting Requirements ...64
10.1.7 Compliance with Law, Audit, and Debarment ............................................ 65
10.1.8 Data Qualit y Assurance ............................................................................... 65
10.1.9 Source Documents ....................................................................................... 66
10.1.10 Study  and Site Closure ................................................................................. 67
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. 68
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 69
10.3.1 Definition of AE .......................................................................................... 69
10.3.2 Definition of SAE ........................................................................................ 70 
  054D4P 
  05KG6X
PRODUCT: V114  8
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
10.3.3 Additional Events Reported ......................................................................... 71
10.3.4 Recording AE and SAE ............................................................................... 71
10.3.5 Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ........................................................................................................ 77
10.4 Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definitions, Collection, and Documentation .................................... 78
10.5 Appendix 5: Contraceptive Guidance ................................................................ 79
10.5.1 Definitions .................................................................................................... 79
10.5.2 Contraception Requirements ........................................................................ 80
10.5.3 Pregnancy  Testing ........................................................................................ 81
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research ............................................................................................ 82
10.7 Appendix 7: Country -specific Requirements .................................................... 87
10.8 Appendix 8: Abbreviations ................................................................................. 88
11 REFERENCES............................................................................................................... 90 
  054D4P 
  05KG6X
PRODUCT: V114  9
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
LIST OF TABLES
Table 1 Study  Interventions .......................................................................................... 28
Table 2 Approximate Blood Volumes Drawn b y Stud y Visit and by Sample Type ....34
Table 3 Reporting Time Periods and Time Frames for Adverse Events and Other 
Reportable Safet y Events ................................................................................. 44
Table 4 Analy sis Strategy  for Immunogenicit y Variables ............................................ 53
Table 5 Analy sis Strategy for Safety  Parameters .......................................................... 55
Table 6 Differences in the Incidence of Adverse Event Rates Between the 
2Vaccination Groups That Can be Detected With an Approximately  80% 
Probability ........................................................................................................ 58 
  054D4P 
  05KG6X
PRODUCT: V114  10
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
LIST OF FIGURES
Figure 1 V114 -020 Study  Design ............................................................................. 14 
  054D4P 
  05KG6X
PRODUCT: V114  11
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Phase 3, Multicenter, Randomized, Double -blind, Active 
Comparator -controlled, Lot -to-Lot Consistency  Study  to Evaluate the Safety , Tolerability , 
and I mmunogenicity  of V114 in Health y Adults 50 Years of Age or Older (PNEU -TRUE)
Short Title: Lot-to-lot consistency of V114 in healthy  adults
Acronym: PNEUmococcal Conjugate Vaccine Trials: V114 -020 (PNEU -TRUE)
Hypotheses, Objectives ,and Endpoints :
Hypotheses are aligned with objectives in the Objectives and Endpoints table.
In health y adults ≥50years of age enrolled in the study :
Primary  Objectives Primary  Endpoints
-Objective: To evaluate the safet y and 
tolerability  of V114 with respect to the 
proportion of participants w ith adverse 
events (AEs).-Solicited injection -site AEs from Day 1 
through Day 5 postvaccination
-Solicited sy stemic AEs from Day 1 through 
Day 14 postvaccination
-Vaccine -related serious adverse events 
(SAEs) from Day 1 to Month 6 
postvaccination
-Objective: To compare the 
seroty pe-specific opsonophagocy tic activity  
(OPA) geometric mean titers (GMTs) at 
30days postvaccination (Day  30) across 
3different lots of V114.
Hypothesis: All 3 lots of V114 are equivalent 
as measured b y the serotype -specific OPA 
GMTs for 15 serot ypes in V114 at 30 day s 
postvaccination.
(The statistical criterion for equivalence 
requires the bounds of the 95% confidence 
interval [CI ] of the GMT ratio for each 
pairwise V114 lot -to-lot comparison of the 
OPA GMT ratio to be within 0.5 to 2.0)-Seroty pe-specific OPA responses for the 
15seroty pes in V114 at Day  30 
  054D4P 
  05KG6X
PRODUCT: V114  12
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Secondary  Objectives Secondary  Endpoints
-Objective: To evaluate the serot ype-specific 
Immunoglobulin G (IgG) geometric mean 
concentrations (GMCs) at 30 day s post 
vaccination (Day 30) compared across the 
3different lots of V114 and combined lots of 
V114 compared to Prevnar 13™.-Seroty pe-specific IgG responses for the 
15seroty pes in V114 at Day  30
-Objective: To evaluate the serot ype-specific 
geometric mean fold ri ses (GMFRs) and 
proportions of participants with a ≥4-fold rise 
from prevaccination (Day 1) to 30 day s 
postvaccination (Day 30) for both OPA and 
IgG responses separatel y across 3 different 
lots of V114.-Seroty pe-specific OPA and IgG responses 
for the 15 serot ypes in V114 at Day 1 and 
Day 30
Overall Desig n:
Study  Phase Phase 3
Primary  Purpose Prevention
Indication Pneumococcal disease
Population Adults 50 y ears of age and older
Study  Type Interventional
Intervention Model Parallel
This is a multi -sitestudy .
Type of Control Active Control Without Placebo
Study  Blinding Double -blind with in -house blinding
Masking Participant or Subject
Investigator
Sponsor 
  054D4P 
  05KG6X
PRODUCT: V114  13
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Estimated Duration o f Study The Sponsor estimates that the study will require 
approximately 11 months from the time the first participant 
signs the informed consent until the last participant’s last 
study -related telephone call or visit.
For purposes of analy sis and reporting, the overall study  
ends when the Sponsor receives the las t laboratory result or 
at the time of final contact with the last participant, 
whichever comes last.
Number of Participant s:
Approximately  2220 participants will be randomized , with approximately  667 participants in 
each V114 intervention group and 220 participants in the Prevnar 13™intervention group.
Intervention Groups and Du ration :
Intervention 
Group s
Intervention 
Group Name VaccineDose 
StrengthDose 
FrequencyRoute 
of 
Admin .Vaccination 
Regimen Use
V114 Lot 1 V114 Refer to IBSingle 
DoseIMSingle Dose 
at Visit 1 
(Day 1)Experimental
V114 Lot 2 V114 Refer to IBSingle 
DoseIMSingle Dose 
at Visit 1 
(Day 1)Experimental
V114 Lot 3 V114 Refer to IBSingle 
DoseIMSingle Dose 
at Visit 1 
(Day 1)Experimental
Prevnar 13™Prevnar 13™Refer to 
product 
labelingSingle 
DoseIMSingle Dose 
at Visit 1 
(Day 1)Experimental
Abbreviations: Admin. = administration; IB = Investigator’s Brochure; IM = intramuscular.
Total 
Number4intervention groups
Duration of 
ParticipationEach participant will participate in the study  for approximately  6months from 
the time the participant signs the Informed Consent F orm (ICF) through the 
final contact. 
  054D4P 
  05KG6X
PRODUCT: V114  14
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Study Governance Committees:
Steering Committee No
Executive Oversight Committee Yes
Data Monitoring Committee Yes
Clinical Adjudication Committee No
Study  governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :Yes
A list of abbreviations used in this document can be found in Appendix 8.
1.2 Schema
The key components of the study  design are depicted in Figure 1.
Figure 1V114 -020 Study  Design
 
  054D4P 
  05KG6X
PRODUCT: V114  15
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
1.3 Schedule of Activities (SoA)
Study Period Intervention Notes
Visit Number 1Telephone 
Contact2Telephone 
Contact
Scheduled Time Day 1 Day 15 Day 30 Month 6
Visit WindowsDay 15 to 
Day 19 after 
Visit 1Day 30 to 
Day 44 after 
Visit 1Day 166 to 
Day 194 
After Visit 1
Administrative Procedures
Screening Procedures
Informed Consent X Consent must be obtained before any study procedures .
Informed Consent for Future Biomedical Research XParticipation in future biomedical research is optional and 
consent must be obtained before the blood sample (DNA 
sample) is collected .
Assignment of Screening Number X
Inclusion/Exclusion Criteria XReview of prior medications/vaccinations, a complete physical 
examination, and temperature measurement are required at 
Visit 1 to determine eligibility.
Medical History XThe participant’s relevant medical history for the 5 years prior 
to study entry will be reviewed. History of tobacco use will 
also be collected for all particip ants.
Post-Random ization Procedures
Assignment of Randomization Number X
Participant Identification Card X
Prior/Concomitant Medication and Non -Study 
Vaccination ReviewX X X
V114 /Prevnar 13™Administration (Blinded) XParticipants will receive either a single dose of V114 or a 
single dose of Prevnar 13™.
Provide electronic Vaccination Report Card (eVRC) XParticipants will be provided an eVRC to record adverse events 
(AEs) and body temperature measurements (see Section 8.3.4 
for details).
Review eVRC Data With Participant X X See Section 8.1.9 for details .
Collect eVRC From Participant X
Complete Telephone Contact Questionnaire X See Section 8.1.10 for details . 
  054D4P 
  05KG6X
PRODUCT: V114  16
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Study Period Intervention Notes
Visit Number 1Telephone 
Contact2Telephone 
Contact
Scheduled Time Day 1 Day 15 Day 30 Month 6
Visit WindowsDay 15 to 
Day 19 after 
Visit 1Day 30 to 
Day 44 after 
Visit 1Day 166 to 
Day 194 
After Visit 1
Safety Procedures
Complete Physical Examination XTo be performed by the investigator or medically qualified 
designee before vaccine is administered .
Pregnancy Test – if applicable XA pregnancy test consistent with local requirements (sensitive 
to at least 25 IU beta human chorionic gonadotropin [β-hCG]) 
must be performed before administration of study vaccine in 
females who are of reproductive potential (see Section 8.3.2 for 
details).
Body Temperature Measurement XEach participant’s body temperature must be taken before 
vaccination (see Section 8.3.3 for details). Participants who 
have febrile illness occurring at or within 72 hours of Visit 1 
must be rescheduled (see Section 5.2 for details).
30-Minute Postvaccination Observation Period X To be performed by blinded study site personnel only.
Adverse Event (AE) Monitoring X X X XNonserious AEs are to be reported from Days 1 through 
14following vaccination. Serious AEs (SAEs) and deaths are 
to be reported throughout the duration of an individual’s study 
participation (see Section 8.4.1 for details).
Immunogenicity Procedures
Serum for immunogenicity assays (including 
retention serum)X XDay 1 blood samples must be collected before vaccination (see 
Section 4.1 and Section 8.8 for details).
Future Biomedical Research
Blood (DNA) for Future Biomedical Research XSample will be collected from randomized participants who 
provided consent for future biomedical research (see 
Section 8.8). The sample should be obtained only at Visit 1 
(Day 1) before vaccine is administered (or with the next 
scheduled blood draw) as the last sample drawn, or at a later 
date as soon as the informed consent is obtained. 
  054D4P 
  05KG6X
PRODUCT: V114  17
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
2 INTRODUCTION
Merck Sharp & Dohme Corp. (MSD) is developing an investigational 15 -valent 
pneumococcal conjugate vaccine (PCV) (referred to as V114) for the prevention of 
pneumococcal disease caused by  the serot ypes in the vaccine. V114 contains the 13 serot ypes 
(1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) present in the licensed vaccine 
Prevnar 13™ (pneumococcal 13 -valent conjugate vaccine [diphtheria CRM 197protein] , 
Wyeth Pharmaceuticals, a subsidiary  of Pfizer, Inc., Philadelphia, PA) , plus 2 additional 
seroty pes (22F and 33F).
2.1 Study Rationale
This study  is conducted in healthy , pneumococcal vaccine naïve adults ≥50 y ears of age to 
demonstrate the consistency  of 3 different lots of V114 with respect to the safet y, tolerabilit y, 
and immunogenicit y of V114. This study  will contribute to the overall safety  database and 
immunogenicit y profile of V114 to support initial licensure in adults.
2.2 Background
2.2.1 V114 and Pneumococcal Disease
Refer to the Investigator’s Brochure (IB) for detailed backgr ound, including information on 
pneumococcal disease burden.
Streptococcus pneumoniae is a significant cause of disease worldwide, with clinical 
manifestations including pneumonia, meningitis, otitis media, sinusitis, and sepsis. Adults 
with comorbid conditions, in particular immunocompr omised individuals, have a higher 
incidence of invasive pneumococcal disease (I PD) morbidity  and mortality  in all age groups 
compared to adults without the comorbid conditions [Lexau, C. A., et al 2005] .
Current ly licensed PCVs (eg, Prevnar™, Sy nflorix™, and Prevnar 13™) were first 
implemented in infant immunization programs in many countries worldwide. Prevnar™ was 
first licensed in 2000 and later replaced b y Prevnar 13™ in 2009 for the European Union and 
in 201 0 for the United States (US) . Although Prevnar 13™ is indicated for both children and 
adults, Sy nflorix™ is only  indicated for children up to 5 y ears of age. Widespread use of 
PCVs has reduced the burden of pneumococcal disease caused b y the serotypes cont ained in 
the vaccines in children who were targeted b y the vaccination programs and unvaccinated 
individuals from other age groups (herd protection) [Centers for Disease Control and 
Prevention 2008] [Ruckinger, S., et al 2009] [Farrell, D. J, et al 2007] [Pilishvili, Tamara, et 
al 2010] [L exau, C. A., et al 2005] [Metlay, J. P., et al 2006] [Whitney , Cynthia G ., et al 
2003] [Moore, M. R., et al 2015] [L epoutre, A., et al 2015] [Weiss, S., et al 2015] 
[Martinelli, D., et al 2014] [Guevara, M., et al 2016] [Waight, P. A., et al 2015] [Jokinen, J., 
et al 2015] [Palmu, A. A., et al 2015] [Wagenvoort, G. H., et al 2 016]. Prevnar 13™ was also 
shown to be efficacious against vaccine -type nonbacteremic pneumococcal pneumonia and
IPD in adults ≥65years of age [Bonten, M. J., et al 2015] . These study  results were the basis 
of the recommendation from the US Advisory  Committee on I mmunization Practices for the 
sequential administration of Prevnar 13™ followed at least 12 months later by   
  054D4P 
  05KG6X
PRODUCT: V114  18
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
PNEUMOVAX™23 i n adults ≥65years of age [Tomczy k, S., et al 2014] [Kobay ashi, M., et 
al 2015] .
Although cases of IPD have decreased following implementation of vaccine campaigns with 
PCVs, an increase in IPD caused b y serot ypes not covered b y currently  available PCV shas 
been observed. V114 contains 2 additional seroty pes (22F and 33F) compared with 
Prevnar 13™ ,and t he selection of 22F and 33F was primarily  based on epidemiological 
importance of these 2 additional seroty pes. By 2012 to 2013 in the US,22F wasthe mos t 
common seroty pe not included in Prevnar 13™ in adults ≥18 y ears of age, causing 13% of 
IPD cases. Serot ype 33F wasassociated with an additional 5% of I PD cases [Moore, M. R., 
et al 2015] . Data from the United Kingdom also showed that, in 2013/2014, 22F and 33F 
were among the leading seroty pes in adults ≥65 years of age, accounting for approximately  
10% and 4% of IPD cases in that age group, respectively  [Waight, P. A., et al 2015] . Data 
from 2014 reported in the 2016 annual epidemiological report on IPD b y the European 
Centre for Disease Prevention and Control showed that both serotypes 22F and 33F are 
among the most common seroty pes causing I PD [European Centre for Disease Prevention 
and Control 2016] .
The additional serot ypes included in V114 will provide broad ercoverage against the leading 
seroty pes associated with pneumococcal disease worldwide. V114 is designed to mee t 
continuing medical and public health needs for PCVs globall y, as well as address the 
emergence of pneumococcal disease caused b yseroty pes not contained in currentl y licensed 
PCVs.
2.2.2 Preclinical and Clinical Studies
Refer to the IB for information on completed preclinical and clinical studies conducted with 
V114.
2.2.3 Information on Other Study -Related Therapy
Prevnar 13™
Refer to approved labeling for detailed background information on Prevnar 13™.
Prevnar 13™ contains all of the pneumococcal seroty pes inc luded in Prevnar™ (4, 6B, 9V, 
14, 18C, 19F, and 23F) plus 6 additional seroty pes (1, 3, 5, 6A, 7F, and 19A).
The adult indication was approved based on immune responses elicited b y Prevnar 13™ in 
comparison with PNEUMOVAX™23. A placebo -controlled clinical efficacy  study
(Community  Acquired Pneumonia I mmunization Trial in Adults [CAPiTA]) evaluated the 
efficacy  of Prevnar 13™ against pneumococcal pneumonia and IPD in immunocompetent 
adults ≥65 y ears of age. Results from CAPiTA showed that Prevnar 13™ was 45. 6% 
(95% confidence interval [CI ]:21.8% to 62.5%) efficacious against vaccine -type 
nonbacteremic pneumococcal pneumonia and 75.0% (95% CI: 41.4% to 90.8%) efficacious 
against vaccine -type IPD in adults ≥65 y ears of age [Bonten, M. J., et al 2015] . 
  054D4P 
  05KG6X
PRODUCT: V114  19
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Prevnar™ and Prevnar 13™ are also known as Prevenar™ and Prevenar 13™ in many  
countries outside of the US. These vaccines are referred to as Prevnar™ and Prevnar 13™ 
throughout this document.
2.3 Benefit/Risk Asse ssment
It cannot be guaranteed that participants in clinical studies will directly  benefit from 
vaccination with V114 during participation, as clinical studies are designed to provide 
information about the safety  and effectiveness of an investigational medicine.
Approximately  220 participants will receive Prevnar 13™, the standard of care, as the active 
comparator in this study . V114 is expected to provide comparable immune responses to 
Prevnar 13™for the shared serot ypes while providing additional coverage for the 2 serot ypes 
(22F and 33F) unique to V114. I t is unknown if the investigational V114 will have the same 
clinical benefit as Prevnar 13 ™.
Additional details regarding specific benefits and risks for participants participating in this 
clinical study  may  be found in the accompanyi ng IB and informed consent documents.
3 HYPOTHESE S, OBJECTIVES ,AND ENDPOINTS
Hypotheses are aligned with objectives in the Objectives and Endpoints table.
In healthy adults ≥50years of age enrolled in the study :
Objectives Endpoints
Primary
Objective : To evaluate the safet y and 
tolerability  of V114 with respect to 
the proportion of participants with 
adverse events (AEs).Solicited injection -site AEs from 
Day 1 through Day 5 postvaccination
Solicited sy stemic AEs from Day 1 
through Day 14 postvaccination
Vaccine -related serious adverse 
events (SAEs) from Day 1 to 
Month 6postvaccination 
  054D4P 
  05KG6X
PRODUCT: V114  20
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Objectives Endpoints
Objective: To compare the 
seroty pe-specific opsonophagocy tic 
activity  (OPA) geometric mean titers 
(GMTs) at 30 days postvaccination 
(Day  30) across 3 different lots of 
V114.
Hypothesis: All 3 lots of V114 are 
equivalent as measured by the 
seroty pe-specific OPA GMTs for 
15seroty pes in V114 at 30days 
postvaccination .
(The statistical criterion for 
equivalence requires the bounds of 
the 95% confidence interval [CI ]of 
the GMT ratio for each pairwise 
V114 lot-to-lot comparison of the 
OPA GMT ratio to be within 0.5to
2.0)Seroty pe-specific OPA responses for 
the 15 serot ypes in V114 at Day 30
Secondary
Objective: To evaluate the 
seroty pe-specific Immunoglobulin G 
(IgG) geometric mean concentrations 
(GMCs) at 30 day s post vaccination 
(Day 30) compared across the 
3different lot s of V114 an d combined 
lots of V114 co mpared to 
Prevnar 13™ .Seroty pe-specific IgG responses for 
the 15 serot ypes in V114 at Day 30
Objective : To evaluate the 
seroty pe-specific geometric mean fold 
rises (GMFRs )and proportions of 
participants with a ≥4-fold rise from 
prevaccination (Day 1) to 30 day s 
postvaccination (Day 30) for both 
OPA and IgG responses separately  
across 3 different lots of V114.Seroty pe-specific OPA and IgG 
responses for the 15 serotypes in 
V114 at Day 1 and Day 30 
  054D4P 
  05KG6X
PRODUCT: V114  21
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
4 S TUDY DESIGN
4.1 Overall Design
This is a randomized, active- controlled, parallel -group, multi -site, double -blind/mask study  
of V114 in adults 50 y ears of age or older .
Approximately  2220 participants will be randomized in a 3:3:3:1 ratio to 1of 4vaccination 
groups ( approximately  667participants per V114 armand220participants in the 
Prevnar 13™ arm): V114 L ot 1, V114 Lot 2, V114 L ot 3, and Prevnar 13™. Randomization 
will be stratified by  participant age at enrollment (50to 64 years, 65 to 74 years, and 
≥75years)
.Approximately  50% of the participants will be ≥65 y ears of age .
Participants will be followed for solicited injection -siteAEs from Day 1 through Day 5 
postvaccination and solicited systemic AEs from Day 1through Day  14 postvaccination . In 
addition, participants will be followed for non -solic ited injection -site and sy stemic AEs 
through Day 14 postvaccination. Information for SAEs and deaths, regardless of whether the 
events are considered to be vaccine related b y the investigator, will be collected from the 
time consent is signed through completion of participation in the study . An external Data 
Monitoring Committee (DMC) will conduct a periodic review of safet y and tolerability  data 
for the adult V114 Phase 3 program. A description of the structure andfunction of the DMC, 
along with the timing and content of the safet y reviews will be outlined in the DMC charter. 
Information regarding the composition of the DMC is provided in Appendix 1.
Blood samples for immunogenicity  assay s will be drawn immediately before V114 or 
Prevnar 13™ vaccinati on at Visit 1 (Day 1) and at 30 day s postvaccination at Visit 2 
(Day 30).
After completion of OPA and electrochemiluminescence (ECL) testing, serum samples will 
be stored to conduct an y additional study -related testing as required by regulatory  agencies or
the Sponsor. Leftover sera from the stud y ma y be used for the development and/or validation 
of pneumococcal assay s after completion of all study -related immunogenicity  testing; this 
applies only  to sera received from stud y participants who provided consen t for future 
biomedical research.
In countries that recommend sequential administration of Prevnar 13™ followed at least 
12months later by  PNEUMOVAX ™23, PNEUMOVAX ™23 will be administered outside 
of this study  protocol .
Specific procedures to be performed during the study , as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3 . Details of each procedure 
are provided in Section 8 .
4.2 Scientific Rationale for Study Design
This study  will serve as a lot -to-lotconsi stency  study  for licensure of V114. This study  is 
conducted to demonstrate the consistency  of the antibody  response to 3 different  
  054D4P 
  05KG6X
PRODUCT: V114  22
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
manufactured lots of V114 in a population (ie, healthy  adults ≥50 y ears of age) at elevated 
risk for pneumococcal disease and its associated morbidity  and mortality .Prevnar 13 ™was 
included as the active comparator in this study to better characterize the safety profile of 
V114 .
The incidence of IPDis directly  related to age, with over half of all cases occurring in adults 
50 years of age or older [Drijkoningen, J. J 2014] .The population of subjects included in this 
study  (healthy  adults ≥50 y ears of age ) is consistent with the indication of pneumococcal 
vaccines, including Prevnar 13™, in health y adults.
Demonstration of lot -to-lotconsistency  is often required by  some national regulatory  
agencies prior to licensure of investigational vaccines. The objec tive of a clinical lot -to-lot 
consistency  study  is to show consistency  of manufacturing and clinical performance of the 
final product b y demonstrating that 3 consecutively manufactured final formulated clinical 
lots of the vaccine display  comparable safet yprofiles and elicit equivalent immune 
responses. The sample size of this study will allow for a high statistical probability  to 
demonstrate consistency  of the immune response across 3lots of V114, while also bolstering 
the size of the overall safety database of the clinical development program .
Participants will be stratified by age group based on observations from previous V114 adult 
studies, where individuals ≥75 y ears of age showed lower post -vaccination immunogenicit y 
responses (based on OPA respo nse) for several seroty pes compared with individuals 50 to 
64and 65 to 74 y ears of age .
4.2.1 Rationale for Endpoints
4.2.1.1 Immunogenicity Endpoints
The immunogenicit y endpoints and associated comparative statistical criteria are consistent 
with previous studies eval uating PCVs.
Sera from participants will be used to measure vaccine -induced, serot ype-specific OPA and 
IgG responses for all 15 seroty pes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 
and 33F) included in V114 using the Multiplexed Opsonophagoc ytic Assay  (MOPA) and 
pneumococcal electrochemiluminescence (PnECL) assay .
Several studies have shown a positive correlation between serot ype-specific IgG antibody  
concentrations and OPA titers in children and adults [Centers for Disease Control and 
Prevention 2010] [Anttila, M., et al 1999] [Romero -Steiner, S., et al 1997] . OPA assesses 
levels of functional antibodies capable of opsonizing pneumococcal capsular polysaccharides 
for presentation to p hagocy tic cells for engulfment and subsequent killing, and therefore is 
considered an important immunologic surrogate for protection against I PD in adults. I t is 
noted that threshold values that correlate with protection in adults have not been defined for
either assay ;however ,the OPA functional assay  is considered a preferred endpoint in adults .
Details on the immunogenicity  endpoints evaluated in this study  can be found in 
Section 9.4.1. 
  054D4P 
  05KG6X
PRODUCT: V114  23
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
4.2.1.2 Safety Endpoints
The safet y endpoints (ie, AEs and temperature) evaluated in this study  were selected based 
on the product’s safet y profile demonstrated in previous studies, published data from 
marketed PCVs, and feedback received from regulatory agencies during product 
development. The electronic Vaccination Report Card (eVRC) used to record AEs during the 
postvaccination periods, as defined in Section 8.1.9, was structured as recommended in the 
final US Food and Drug Administration P atient- Reported Outcome Guidance [U.S. Food and 
Drug Administration 2009] .
Details on the safet y endpoints evaluated in this study  can be found in Section 8.3.4 and 
Section 9.4.2.
Details on AEs, including definitions and reporting requirements, can be found in 
Appendix 3.
4.2.1.3 Pharmacokinetic Endpoi nts
Pharmacokinetic ( PK)parameters will not be evaluated in this study .
4.2.1.4 Pharmacodynamic Endpoints
Pharmacod ynamic parameters will not be evaluated in this study .
4.2.1.5 Future Biomedical Research
The Sponsor will conduct future biomedical r esearch on specimens for which consent was 
provided during this study . This research may  include genetic anal yses (DNA), gene 
expression profiling ( ribonucleic acid [ RNA ]), proteomics, metabolomics (serum, plasma), 
and/or the measurement of other analy tes, depending on whi ch specimens are consented for 
future biomedical r esearch.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study ) and will only  be conducted on specimens from 
appropriatel y consented participants. The objective of coll ecting/retaining specimens for 
future biomedical r esearch is to explore and identify  biomarkers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to us e 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the correct drug/vaccine at the cor rect time. The 
details of this future biomedical r esearch substudy  are presented in Appendix 6.
4.2.2 Rationale for the Use of Comparator/Placebo
Placebo -controlled clinical studies for new PCVs are no longer feasible given the proven 
clinical efficacy  and widespread use of licensed PCVs worldwide. Prevnar 13™ is currentl y 
a recommended vaccine for t he prevention of pneumococcal disease in the US and is also  
  054D4P 
  05KG6X
PRODUCT: V114  24
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
used in many  other countries worldwide. It will be used as the active comparator in this study
and will allow for an unbiased assessment of safety.
4.3 Justification for Dose
The concentrations of pne umococcal poly saccharide and adjuvant in V114 have been 
established in previous clinical studies. The dosing regimen of V114 is similar to that used in 
previous adult V114 clinical studies in which 1 dose has resulted in a robust immune 
response (refer to the V114 IB for more detailed information on dose selection ).
4.4 Beginning and End of Study Definition
The overall study  begins when the first participant signs the ICF. The overall study  ends 
when the last participant completes the last study -related telepho ne-call or visit, withdraws 
from the study , or is lost to follow -up (ie, the participant is unable to be contacted b y the 
investigator) .
For purposes of analy sis and reporting, the overall study  ends when the Sponsor receives the 
last laboratory  result or at the time of final contact with the last participant, whichever comes 
last.
4.4.1 Clinical Criteria f orEarly Study Termination
There are no prespecified criteria for terminating the study  early.
5 STUDY POPULATION
Health ymale and female participants ≥50years of ag e will be enrolled in this study .
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
A participant will be eligible for inclusion in th estudy  if the participant :
1.In the opinion of the investigator, i s in good health. Any  underl ying chronic condition 
must be documented to be stable according to the investigator’s judgment .
Demographics
2.Ismale or female ≥50yearsof age at the time of signing the informed consent. 
  054D4P 
  05KG6X
PRODUCT: V114  25
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Female Participants
Contraceptive use b y women should be consistent with local regulations regarding the 
methods of contraception for those participating in clinical studies .
3.Afemale participant is el igible to participate if she is not pregnant (Appendix 5), not 
breastfeeding, and at least 1 of the following conditions applies:
a.Not a woman of childbearing potential (WOCBP) as defined in Appendix 5.
OR
b.A WOCBP who agrees to use 1 of the contraceptive me thods as defined in 
Appendix 5 during the treatment period and for at least 6 weeks after the last dose of 
study  intervention.
Informed Consent
4.Provides written informed consent for the stud y. The participant may also provide 
consent for future biomedical research. However, the participant may  participate in the 
main study  without participating in future biomedical research.
5.2 Exclusion Criteria
The p articipant must be excluded from the study  if the participant:
Medical Conditions
1.Has a h istory  of IPD (positi ve blood culture, positive cerebrospinal fluid culture, or 
positive culture at another sterile site) or known history of other culture -positive 
pneumococcal disease within 3 y ears of Visit 1 (Day 1).
2.Has a k nown h ypersensitivity  to any  component of pneumoc occal pol ysaccharide 
vaccine, PCV , or any  diphtheria toxoid -containing vaccine.
3.Has a k nown or suspected impairment of immunological function including, but not 
limited to, a history  of congenital or acquired immunodeficiency , documented human 
immunodefici ency  virus ( HIV)infection, functional or anatomic asplenia, or history  of 
autoimmune disease (including but not limited to the autoimmune conditions outlined in 
the Investigator Trial File Binder for this study ).
4.Has a c oagulation disorder contraindicatin g intramuscular vaccinations.
5.*Had a r ecent febrile illness (defined as oral or tympanic temperature ≥100.4°F 
[≥38.0°C] oraxillary  or temporal temperature ≥99.4°F [≥37.4°C] )or received antibiotic 
therap y for an y acute illness occurring within 72 hours be fore receipt of study  vaccine. 
  054D4P 
  05KG6X
PRODUCT: V114  26
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
6.Has a h istory  of malignancy  ≤5 years prior to signing informed consent, except for 
adequatel y treated basal cell or squamous cell skin cancer or in situ cervical cancer .
7.A WOCBP has a positive urine or serum pregnancy test before the first vaccination at 
Visit 1 (Day 1).
Prior/Concomitant Therapy
8.Has received any pneumococcal vaccine or is expected to receive an y pneumococcal 
vaccine during the study  outside of the protocol.
9.Has r eceived systemic corticosteroids (prednisone equivalent of ≥20 mg/day ) for 
≥14consecutive day s and has not completed intervention at least 30 day s before stud y 
entry .
10.Has r eceived systemic corticosteroids exceeding phy siologic replacement doses 
(approximately  5 mg/day prednisone equivalent) within 1 4 day s before vaccination. 
(Note : Topical, ophthalmic, intra -articular or soft -tissue [eg, bursa, tendon steroid 
injections], and inhaled/nebulized steroids are permitted).
11.Is receiving immunosuppressive therapy , including chemotherapeutic agents used to t reat 
cancer or other conditions, and interventions associated with organ or bone marrow 
transplantation, or autoimmune disease.
12.*Has r eceived any  non-live vaccine within the 14 day s before receipt of anystudy  
vaccine or is scheduled to receive an y non -live vaccine within 30 day s following receipt 
of anystudy  vaccine. Exception : Inactivated influenza vaccine may  be administered but 
must be given at least 7 day s before receipt of anystudy  vaccine or at least 15 day s after 
receipt of anystudy  vaccine.
13.*Hasreceived any  live vaccine within 30 day s before receipt of anystudy  vaccine or is 
scheduled to receive an y live vaccine within 30 days following receipt of anystudy  
vaccine.
14.Has r eceived a blood transfusion or blood products, including immunoglobulin ,within 
the 6 months before receipt of study  vaccine or is scheduled to receive a blood 
transfusion or blood product within 30 day s of receipt of study  vaccine. Autologous 
blood transfusions are not considered an exclusion criterion.
Prior/Concurrent Clini cal Study Experience
15.Is currently  participating in or has participated in an interventional clinical study  with an 
investigational compound or device within 2 months of participating in this current stud y. 
  054D4P 
  05KG6X
PRODUCT: V114  27
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Other Exclusions
16.In the opinion of the investigator, has a history  of clinically relevant drug or alcohol 
abuse that would interfere with participation in protocol -specified activities.
17.Has history  or current evidence of any  condition, therap y, lab oratory abnormality ,or 
other circumstance that might expose the participant to risk by  participating in the stud y, 
confound the results of the study , or interfere with the participant’s participation for the 
full duration of the study .
18.Is or has an immediate family  member (eg , spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study.
For items with an asterisk (*), if the participant meets these exclusion criteria, the 
Day 1 Visit may be rescheduled for a time when these criteria are not met.
5.3 Lifestyle Considerations
No lifesty le restrictions are required.
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study, but 
are not subsequently randomized in the study . A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulator y authorities . Minimal information includes demograph y, 
screen failure details, eligibility criteria, and any AEs or SAEs meeting reporting 
requirements as outlined in the data entry guidelines.
5.5 Participant Replacement Strategy
A participant who withdraws from the stud ywill not be replaced .
6 STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according to 
the study  prot ocol.
Clinical supplie s [V114 , Prevnar 13™
]will be packaged to support enrollment . Clinical 
supplies will be affixed with a clinical label in accordance with regulatory requirement s.
6.1 Study Intervention(s) Administered
The study intervention s to be used in this study are outlined inTable 1. 
  054D4P 
  05KG6X
PRODUCT: V114  28
PROTOCOL/AMENDMENT N O.:020-00 
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Table 1 Study  Intervention s
Arm  
Nam eArm  TypeIntervention 
Nam eTypeDose 
Form ulationUnit 
Dose 
StrengthDosage 
LevelRoute 
of 
AdminVaccination 
Regim enUseIMP/
NIMPSourcing
V114 
Lot 1Experimental V114 Biological/
VaccineSterile 
Suspension 
(Prefilled 
Syringe)Refer to 
IB0.5 mL IM Single dose 
at Visit 1 
(Day 1)Experimental IMP Central
V114 
Lot 2Experimental V114 Biological/
VaccineSterile 
Suspension 
(Prefilled 
Syringe)Refer to 
IB0.5 mL IM Single dose 
at Visit 1 
(Day 1)Experimental IMP Central
V114 
Lot 3Experimental V114 Biological/
VaccineSterile 
Suspension 
(Prefilled 
Syringe)Refer to 
IB0.5 mL IM Single dose 
at Visit 1 
(Day 1)Experimental IMP Central
Prevnar 
13™Active 
Com paratorPrevnar 13™ Biological/
VaccineSterile 
Suspension 
(Prefilled 
Syringe)Refer to 
product 
labeling0.5 mL IM Single dose 
at Visit 1 
(Day 1)Experimental IMP Central
Admin = administration; IB = Investigator’s Brochure; IM = intramuscular; IMP = investigational medicinal product; NIMP = non -investigational medicinal 
product.
Definition Investigational Medicinal P roduct (IMP) and Non -Investigational Medicinal Product (NIMP) is based on guidance issued by the European 
Commission. Regional and/or country differences of the definition of IMP/NIMP may exist. In these circumstances, local legislation is followe d. 
  054D4P 
  05KG6X
PRODUCT:   V114  29
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
All supplies indicated in Table 1will be provided per the "Sourcing" column depending upon 
local country operational requirements. Every  attempt should be made to source these 
supplies from a single lot/batch number .
Refer to Section 8.1.8 for details regarding administration of the study  intervention.
6.2 Preparation/Handling/Storage/Accountability
6.2.1 Dose Preparation
There are no specific calculations or evaluations required to be performed in order to 
administer the proper dose to each participant. T he rationale for selection of doses to be used 
in this study  is provided in Section 4.3.
6.2.2 Handling, Storage ,and Accountability
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received, and an y discrepancies are 
reported and resolved before use of the stud y intervention .
Only participants enrolled in the study  may  receive study  intervention , and only  authorized 
site staff may  supply  or administer study  intervention . All study  intervention s must be stored 
in a secure, environmentally  controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y intervent ionaccountability , reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all stud y sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability  and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study  site is re sponsible for recording the lot number, manufacturer, and expiry  date for 
any locall y purchased product (if applicable) as per local guidelines unless otherwise 
instructed by  the Sponsor.
The investigator shall take responsibility  for and shall take all st eps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of stud y 
intervention s in accordance with the protocol and any applicable laws and regulations . 
  054D4P 
  05KG6X
PRODUCT:   V114  30
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
6.3 Measures to Minimize Bias: Randomization and Blind ing
6.3.1 Intervention Assignment
Intervention allocation/r andomization will occur centrally using an interactive response 
technology  (IRT) s ystem. There are 4study  intervention arms. Participants will be assigned 
randomly  in a 3:3:3 :1ratio to V114 L ot 1, V114 Lot 2, V114 L ot 3,and Prevnar 13™,
respectivel y,based on their age strata assignments as defined below .
6.3.2 Stratification
Intervention allocation/randomization will be stratified according to the following factors:
•Age at time of randomization :
-Participants 50 to 64 years of age
-Participants 65 to 74 y ears of age
-Participants ≥75 y ears of age.
Approximately  50% of the participants will be ≥65 y ears of age .
6.3.3 Blinding
A double -blinding technique will be used. V114 and Prevnar 13™will be prepared and/or 
dispensed in a blinded fashion by  an unblinded pharmacist or qualified study site personnel. 
The participant , the investigator, and Sponsor personnel or delegate(s) who are involved in 
the study  intervention administration or clini cal evaluation of the participants are unaware of 
the intervention assignments.
Because V114 and Prevnar 13™have a different appearance, a member of the study  site staff 
will be unblinded for the purposes of receiving, maintaining, preparing and/or dispen sing, 
and administering these study  vaccines. Procedures for handling, preparing, and 
administering the unblinded vaccines are located in the Investigator Trial File Binder.
To avoid bias, the unblinded study personnel will have no further contact with stu dy 
participants for any study -related procedures/assessments after administration of study  
vaccines, which includes all safet y follow -up procedure s. Additionall y, blinded site 
personnel will not be present in the examination room when study vaccines are ad ministered. 
Contact between participants and unblinded study  personnel after vaccination administration 
is strictly  prohibited. Blinded site personnel will be responsible for all safety  and 
immunogenicit y follow -up procedures after vaccine administration .
An unblinded Clinical Research Associate will monitor vaccine accountability  at the study  
site. All other Sponsor personnel or delegate(s) and Merck Research Laboratories employ ees  
  054D4P 
  05KG6X
PRODUCT:   V114  31
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
directly  involved with the conduct of this study  will remain blinded to the participant-level 
intervention assignment.
See Section 8.1.10 for a description of the method of unblinding a participant during the 
study  should such action be warranted.
6.4 Study Intervention Compliance
Given that a single dose of V114 or Prevnar 13™will be administered in this study ,
intervention compliance will not be assessed.
6.5 Concomitant Therapy
Medications or vaccinatio ns specificall y prohibited in the exclusion criteria are not allowed
during the ongoing stud y (see Section 5.2). I f there is a c linical indication for an y 
medications or vaccinatio nsspecificall y prohibited, di scontinuation from study  intervention 
may be required. The investigator should discuss any  questions regarding this with the 
Sponsor Clinical Director . The final decision on anysupportive therap y or vaccination rests 
with the investigator and/or the participant ’s primary  physician. However, the decision to 
continue the participant on study  intervention requires the mutual agreement of the 
investigator, the Sponsor, and the pa rticipant.
Listed below (items 1 to 4) are specific restrictions for concomitant therapy or vaccination
during the course of the study :
1.Any administration of a non -study  pneumococcal vaccine is prohibited during the stud y.
2.Live and non -live vaccines may  only be administered prior to or following the receipt of 
study  vaccine according to the time frames specified in Exclusion Criteria (Section 5.2). 
Exception : Inactivated influenza vaccine may  be administered but must be given at least 
7 day s before receipt of study  vaccine or at least 15 days after receipt of any  study  
vaccine.
3.Participants should not receive s ystemic corticosteroids (prednisone equivalent of 
≥20mg/day  for ≥14 consecutive day s) starting from 30 days prior to through 30 days 
following vaccin ation.
4.Participants should not receive s ystemic corticosteroids exceeding ph ysiologic 
replacement doses (prednisone equivalent dose >5 mg/day ) within 14 days before any  
vaccination.
Note : Topical, ophthalmic, intra -articular or soft -tissue (eg, bursa, tend on steroid 
injections), and inhaled/nebulized steroids are permitted.
Any deviation from the above requires consultation between the investigator and the Sponsor 
and written documentation of the collaborative decision on participant management. 
  054D4P 
  05KG6X
PRODUCT:   V114  32
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
6.5.1 Rescue Medications and Supportive Care
No rescue or supportive medications are specified for use in this study .
6.6 Dose Modification (Escalation/Titration/Other)
No dose modification is allowed in this study .
6.7 Intervention After the End of the Study
There is no stud y-specified intervention following the end of the stud y.
6.8 Clinical Supplies Disclosure
This study  is blinded but supplies are provided open label; therefore, an unblinded 
pharmacist or unblinded qualified study  site personnel will be used to maintain the blinding 
of study  staff who are directly  involved in the clinical evaluation of participants in the study . 
Study  intervention identity  (name, strength, or potency ) is included in the label text; random 
code/disclosure envelopes or lists are n ot provided.
The emergency  unblinding call center will use the intervention /randomization schedule for 
the study  to unblind participants and to unmask study  intervention identity . The emergency  
unblinding call center should only  be used in cases of emergen cy (see Section 8.1.10). In the 
event that the emergency unblinding call center is not available for a given site in this study , 
the central electronic intervention allocation/randomization system (IRT) should be used to 
unblind participants and to unmask study  intervention identity . The Sponsor will not provide 
random code/disclosure envelopes or lists with the clinical supplies.
See Section 8.1.1 2for a description of the method of unblinding a participant during the 
study , should such action be warranted .
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
WITHDRAWAL
7.1 Discontinuation of Study Intervention
In clinical studies with a single intervention, discontinuation of study intervention can onl y 
occur prior to the intervention and generall y represents withdrawal from the study .
Participants who receive a single -dose intervention cannot discontinue study intervention.
7.2 Participant Withdrawal From the Study
A participant must be withdrawn from the study  if the participant withdraws consent from the 
study .
If a participant withdraws from the study, they will no longer receive stud y intervention or be 
followed at scheduled protocol visits. 
  054D4P 
  05KG6X
PRODUCT:   V114  33
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Specific details regarding procedures to be performed at the time of withdrawal from the 
study ,as well as specific details regarding withdrawal from future biomedical r esearch, are 
outlined in Section 8.1.11 . The procedures to be performed should a participant repeatedl y 
fail to return for scheduled visits and/or if the study site is unable to contact the participant 
are outlined in Section 7.3.
7.3 Lost to Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact the participant, the following procedures are to be performed:
•The site must attempt to contact the participant and reschedule the missed visit. I f the 
participant is contacted, the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
•The investigator or designee must make every  effort to regain contact with the participant 
at each missed visit (eg, telephone calls and/or a certified letter to the participant’s last 
known mailing address or locally  equivalent methods). These contact attempts should be 
documented in the participant’s medical record.
•Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and anal ysis guidelines .
8 STUDY ASSESS MENTS AND PROCEDURES
•Study  procedures and their timing are summarized in the SoA.
•Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
•The investigator is responsible for ensuring t hat procedures are conducted by  
appropriatel y qualified (by education, training, and experience) staff. Delegation of study  
site personnel responsibilities will be docu mented in the I nvestigator Trial File Binder (or 
equivalent).
•All study -related medica l decisions must be made by  an investigator who is a qualified 
physician .
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable. 
  054D4P 
  05KG6X
PRODUCT:   V114  34
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
•Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of ICF may  be utilized for screening or baseline 
purposes provided the procedure met the protocol -specified criteria and were performed 
within the time frame defined in the SoA.
•Additional evaluations/testing may  be deemed necessary  by the investigator and or the 
Spon sor for reasons related to participant safet y. In some cases, such evaluation/testing 
may be potentially  sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. I n these 
cases, such evaluations/testing will be performed in accordance with those regulations.
The maximum amount of blood collected from each participant for stud y procedures at each 
study  visit will not exceed 30 mL  and the total amount of blood for the entire study  collected 
during planned study  visits will not exceed 50 mL (Table 2).
Repeat or unscheduled samples may  be taken for safet y reasons or for technical issues with 
the samples.
Table 2 Approximate Blood Volumes Drawn b y Study  Visit and by  Sample Ty pe
Study VisitVisit 1
Day 1Visit 2
Day 30Total
Parameter Approximate Blood Volume (mL)
Immunogenicity assays (including retention samples) 20 mL 20 mL 40 mL
DNA for Future Biomedical Research 8.5 mL N/A 8.5 mL
Expected total (mL) 28.5 mL 20 mL 48.5 mL
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically  qualified designee (consistent with local requirements) must 
obtain documented consent from each potential participant prior to particip ating in a clinical 
study or future biomedical r esearch .If there are changes to the participant’s status during the 
study  (eg, health or age of majority  requirements), the investigator or medically  qualified 
designee must ensure the appropriate consent is in place.
8.1.1.1 General Informed Consent
Consent must be documented by  the participant’s dated signature on a consent form along 
with the dated signature of the person conducting the consent discussion.
A cop y of the signed and dated consent form should be given to the participant before 
participation in the study . 
  054D4P 
  05KG6X
PRODUCT:   V114  35
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
The initial I CF, any  subsequent revised written ICF, and an y written information provided to 
the participant must receive the Institutional Review Board/Independent Ethics Committee’s 
(IRB/IEC’s )approval/favorable opinion in advance of use. The participant should be 
informed in a timely  manner if new information becomes available that may be relevant to 
the participant’s willingness to continue participation in the study . The communication of 
this information will be provided and documented via a revised consent form or addendum to 
the original consent form that captures the participant’s dated signature.
Specifics about a stud y and the study population will be added to the consent form template 
at the protocol level.
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, 
and Sponsor requirements .
8.1.1.2 Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically  quali fied designee w ill explain the future biomedical r esearch 
consent to the participant, answer all of his/her questions, and obtain written informed 
consent before performin g any procedure related to the future biomedical research sub study . 
A cop y of the informed consent w ill be given to the participant.
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by the investigator ,who is a qualified 
physician ,to ensure that the participant qualifies for the study .
8.1.3 Participant Identification Ca rd
All participants will be given a participant identification card identify ing them as participants 
in a research stud y. The card will contain study site contact information (including direct 
telephone numbers) to be used in the event of an emergency . The inv estigator or qualified 
designee will provide the participant with a participant identification card immediately after 
the participant provides written informed consent. At the time of intervention
allocation /randomization, site personnel will add the treatment /randomization number to the 
participant identification card.
The participant identification card also contains contact information for the emergency 
unblinding call center so that a healthcare provider can obtain information about study 
intervention i n emergency  situations where the investigator is not available.
8.1.4 Medical Histo ry
A medical history  will be obtained by  the inv estigator or qualified designee before 
vaccination at Visit 1 (Day 1). The participant’s relevant medical history  for the 5 y ears prior 
to Visit 1 (Day 1) will be obtained to ensure that the participant satisfies the inclusion and 
exclusion criteria of the study . History  of tobacco use will also be collected. 
  054D4P 
  05KG6X
PRODUCT:   V114  36
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
8.1.5 Prior and Concomitant Medications Revi ew
8.1.5.1 Prior Medications
The investigator or qualified designee will review prior medication use, including an y 
protocol -specified washout requirement, and record prior medication taken by  the participant 
within 30 days before thestudy  vaccination at Visit 1 (Day 1).
8.1.5.2 Concomitant Medications
The investigator or qualified designee will record medication, if an y, taken by the participant 
during the stud y.
New and/or concomitant medications taken after Visit 1 (Day 1) and non -study  vaccines 
received since Visit 1 will be recorded with the eVRC as specified in Section 8.3.4.
8.1.6 Assignment of Screening Numb er
All consented participants will be given a unique screening number that will be used to 
identify  the participant for all procedures that occur prior to randomizatio n. Each participant 
will be assigned onl y 1 screening number. Screening numbers must not be re -used for 
different participants.
8.1.7 Assignment of Treatment/Randomization Numb er
All eligible participants will be randomly allocated and will receive a 
treatment /rand omization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment allocation/randomization . Once a 
treatment /randomization number is assigned to a participant, it can never be re -assigned to 
another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
8.1.8 Study Intervention Administrati on
Unblinded study  personnel not otherwise involved in the conduct of the study  will prepare 
and administer V114 or Prev nar13™. Study  vaccines should be prepared and administered 
by appropriatel y qualified members of the stud y personnel (eg, ph ysician, nurse, phy sician’s 
assistant, nurse practitioner, pharmacist ,or medical assistant) as allowed b y local/state, 
country ,and institutional guidance. Procedures for handling, preparing, and administering the 
unblinded vaccines are provided in the Investigator Trial File Binder. Unblinded study  
personnel should follow the preparation and administration instructions for Prevnar 13™ as 
specified in the product label.
Study  vaccines should be removed from the refrigerator no more than 1 hour before 
vaccination. The time of removal and time of vaccination should be documented in the 
participant’s chart. 
  054D4P 
  05KG6X
PRODUCT:   V114  37
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Prior to administration of V114, the unblinded pharmacist should shake the product 
vigorousl y to obtain a homogenous white suspension. If white -colored insoluble particle 
appears, the unblinded pharmacist should use rapid, horizontal hand shaking for 5 to 
10seconds while holding the syringe in between the thumb and index finger until complete 
resuspension. This action should be repeated, as necessary . If appearance is otherwise, the 
vaccine should not be administered. The vaccine should not be used if the vaccine cannot be 
resuspended.
Study  vaccine will be administered as a single 0.5 -mL intramuscular injection , preferabl yin 
the deltoid region of the participant’s arm . Adequate treatment provision, including 
epinephrine and equipment for maintaining an airway , should be available for immediate use 
should an anaph ylactic or anaph ylactoid reaction occur [Centers for Disease Control and 
Prevention 2015] .
Unblinded study  personnel should not have contact with participants for any stud y-related 
procedures/assessments after administration of study  vaccines, which includes all safet y 
follow -up procedures. All safet y and immunogenicity assessments will be conducted b y 
blinded personnel, and the participant will be blinded to the study vaccine receive d. 
Vaccination information, such as Component Identification Number and time of vaccination, 
must be recorded on the appropriate electronic Case Report Form ( eCRF )as per the Data 
Entry  Guidelines .
8.1.8.1 Timing of Dose Administration
Vaccinations may  be administered at an y time of day and without regard to timing of meals.
Each participant's body temperature must be taken before vaccine administration. I ndividuals 
who present with fever (oral or t ympanic temperature ≥100.4°F [≥38.0°C] oraxillary  or 
tempo ral temperature ≥99.4°F [≥37.4°C ]) will have the vaccination delayed until fever is 
resolved for at least 72 hours.
The collection of blood samples and administration of pregnancy tests (if applicable) must be 
done before each vaccine administration.
All p articipants will be observed for at least 30 minutes after vaccination for any  immediate 
reactions. This observation must be performed b y blinded site personnel for all study 
vaccines (Section 1.3 and Section 6.3.3).
8.1.9 Electronic Vaccination Report Card (eVR C)
The eVRC was developed to be administered electronically  via a hand -held devic e. This item 
was structured as recommended in the final Food and Drug Administration Patient -Reported 
Outcome Guidance [U.S. Food and Drug Administration 2009] . The investigator or delegate 
will train the participant in the use of the eVRC at Visit 1 (Day 1).
Temperatures, injection -site reactio ns, vaccine -specific complaints, other complaints or 
illnesses, and concomitant medicati ons or vaccinations will be recorded on the eVRC as  
  054D4P 
  05KG6X
PRODUCT:   V114  38
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
described in Section 1.3 and Section 8.3.4. The investigator or delegate will review the data 
captured on the eVRC with the participant at the Telephone Contact (Day 15) and Visit 2 
(Day 30).
Any difference s between eVRC data and the clinical database must be clearly  explained in 
the participant’s source documentation.
For the specific AEs collected via the eVRC, the investigator will use the information 
provided b y the participant both on the eVRC and verba lly at the time of eVRC review to 
apply  the appropriate assessment of intensity  and toxicity  as described in Appendix 3.
8.1.10 Telephone Contact Questionnaire
Site personnel will contact the participant approximately 6 months after the last dose of study 
vaccine to collect additional information based on a Telephone Contact Questionnaire 
provided b y the Sponsor. Data to be reported from this discussion will include SAEs and/or 
any updates to previously  reported safet y information.
8.1.11 Discontinuation and Withdrawal
Participants who receive a single -dose intervention cannot discontinue study intervention 
(see Section 7.1).
When a participant withdraws from participation in the study, all applicable activities 
scheduled for the final study  visit (Visit 2)should be per formed (at the time of withdrawal). 
Any AEs that are present at the time of withdrawal should be followed in accordance with 
the safet y requirements outlined in Section 8.4.
8.1.11.1 Withdrawal From Future Biomedical Resear ch
Participants may withdraw their consent for future biomedical r esearch. Participants may  
withdraw consent at an y time by  contacting the investigator for the main study . If medical 
records for the main study are still available, the investigator will contact the Sponsor using 
the designated mail box (clinical.specimen.management@merck.com). Subsequently ,the 
participant's consent for future biomedical r esearch will be withdrawn. A letter will be sent 
from the Sponsor to the investigator confirming the withdrawal. I t is the responsibility  of the 
in
vestigator to inform the participant of completion of withdrawal. An y analy ses in progress 
at the time of request for withdrawal or alread y performed prior to the request being received 
by the Sponsor will continue to be used as part of the overall researc h study  data and results. 
No new analy ses would be generated after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study  records) 
or the specimens have been completel y anon ymized, there will no longer be a link between 
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed . 
  054D4P 
  05KG6X
PRODUCT:   V114  39
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
8.1.12 Partici pant Blinding/Unblindi ng
STUDY INTERVENT ION IDENT IFICATION INFORMAT ION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency  situations where the investigator or medically  qualifie d designee (consistent 
with local requirements) needs to identify  the intervention used by  a participant and /orthe 
dosage administered , he/she will contact the emergency  unblinding call center by  telephone 
and make a request for emergency  unblinding. As r equested b y the investigator or medically  
qualified designee, the emergency  unblinding call center will provide the information to 
him/her promptly  and report unblinding to the Sponsor. Prior to contacting the emergency  
unblinding call center to request un blinding of a participant’s intervention assignment, the 
investigator who is a qualified phy sician should make reasonable attempts to enter the 
intensity /toxicity  grade of the AEs observed, the relation to study  intervention, the reason 
thereof , etc., in t he medical chart. If it is not possible to record this assessment in the chart 
prior to the unblinding, the unblinding should not be delay ed.
In the event that unblinding has occurred, the circumstances around the unblinding (eg, date, 
reason, and person p erforming the unblinding) must be documented promptly , and the 
Sponsor Clinical Director notified as soon as possible.
Once an emergency  unblinding has taken place, the investigator, site personnel, and Sponsor 
personnel may  be unblinded so that the ap propriate follow -up medical car ecan be provided 
to the participant .
Participants whose trea tment assignment has been unblinded by the investigator or medicall y 
qualified designee and/or nonstudy  treating ph ysician must be discontinued from study  
intervention, but should continue to be monitored in the study .
Additionally , the investigator or medically  qualified designee must go into the I RT sy stem 
and perform the unblind in the I RT sy stem to update drug disposition. In the event that the 
emergency  unblinding c all center is not available for a given site in this study , the IRT 
system should be used for emergency  unblinding in the event that this is required for 
participant safety .
8.1.13 Calibration of Equipme nt
The investigator or qualified designee has the responsibility  to ensure that any  device or 
instrument used for a clinical evaluation/test during a clinica l study  that provides information 
about inclusion/exclusion criteria and/or safety or efficacy  parameters shall be suitably  
calibrated and /ormaintai ned to ensure that the data obtained are reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study  site. 
  054D4P 
  05KG6X
PRODUCT:   V114  40
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
8.2 Immunogenicity Assessmen ts
Sera from participants will be used to measure vaccine -induced OPA and IgG for serot ypes 
included in V114 and Prevnar 13™. These endpoints will be tested for all blood draws. 
Blood collection, storage ,and shipment instructions for serum samples will be provided in 
the operations/laboratory manual.
The MOPA will b e used for measuring OPA GMTs. Opsonization of pneumococci for 
phagocy tosis is an important mechanism by  which antibodies to poly saccharides protect 
against disease in vivo. The OPA assay  is a useful tool for assessing the protective function 
of serot ype-specific antibodies and ,therefore, the immunogenicit y of pneumococcal vaccine 
formulations.
Measurement of serot ype-specific IgG will be measured using the PnECL  v2.0 assay  to 
assess the concentration of binding antibodies to capsular pol ysaccharide of S. pneumoniae
for the serot ypes included in the study  vaccines .
8.2.1 Multiplex Opsonophagocytic Assay (MOPA)
The MOPA, developed and published by  Professor Moon Nahm (Director of the USWorld 
Health Organization pneumococcal serology  reference laboratory  and Natio nal Institutes of 
Health pneumococcal reference laboratories), is a multiplexed OPA assay capable of 
measuring 4 serot ypes at a time, against a total of 16 serotypes of pneumococci [Burton, 
Robert L . and Nahm, M oon H. 2006] . The OPA is an antibody -mediated killing assay  that 
measures the ability  of human serum to kill S. pneumoniae serot ypes with the help of 
complement and phagocy tic effector cells. The ability  of the assay  to simultaneously  test 
4seroty pes/run reduces the amount of serum needed for testing. The assay  readout is the 
opsonization index, which is the reciprocal of th e highest dilution that gives ≥50% bacterial 
killing, as determined b y comparison to assay  background controls. MSD has developed and 
optimized the MOPA in a high throughput micro -colony  platform. The MOPA assay  for all 
15 V114 serot ypes has undergone vali dation. The validation study  evaluated various 
performance parameters of the assay  including precision, relative accuracy/dilutional 
linearity , and specificity . The validation results were evaluated against prespecified 
acceptance criteria for each of the parameters .
8.2.2 Electrochemiluminescence (ECL)
MSD has developed and optimized a multiplex, ECL -based detection method for the 
quantitation of IgG serotype -specific antibodies to the 15 pneumococcal poly saccharide 
seroty pes contained in V114. The PnECL  v2.0 assay  is based on the Meso -Scale Discovery  
technology , which employ s disposable multi -spot microtiter plates. The benefits of the ECL 
multiplex technology  over the prior enz yme-linked immunosorbent assay  methodology  
include speed, equivalent or better sensitivity , increased dy namic range, the ability to 
multiplex, and reduction in required serum sample and reagent volumes. The measurement of 
immune responses to the 15 seroty pes included in V114 is performed using an assay  format 
consisting of 2 groups of 7 and 8 serot ypes each. The PnECL  v2.0 assay  for all 15 seroty pes 
has undergone validation. The validation study evaluated various performance parameters of  
  054D4P 
  05KG6X
PRODUCT:   V114  41
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
the assay  including precision, ruggedness, relative accuracy, dilutional linearity, selectivity, 
and specificit y. The validation results were eval uated against prespecified acceptance criteria 
for each of the parameters .
8.3 Safety Assessments
Details regarding specific safet y procedures/assessments to be performed in this study  are 
provided. The total amount of blood to be drawn over the course of the study  (from prestudy  
to poststudy  visits), including approximate blood volumes drawn b y visit and by sample t ype 
per particip ant, can be found in Section 8 .
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examination
A comp lete ph ysical examination will be conducted by an investigator or medically  qualified 
designee (consistent with local requirements) before vaccination at Visit 1 (Day 1).
A complete ph ysical examination includes , but is not limited to, assessment of genera l 
appearance, vital signs (heart rate, respiratory  rate, blood pressure, and body  temperature) ,
eyes, throat, mouth, cardiovascular, respiratory , gas trointestinal , skin, neurologic ,and 
psychiatric s ystems , and other organ s ystems as indicated .
In the sour ce documents, investigators should document phy sical exam data and the status of 
all active medical conditions.
Investigators should pay  special attention to clinical signs related to previous serious 
illnesses.
8.3.2 Pregnancy Test
A pregnancy  test consistent with local requirements (sensitive to at least 25 IU beta human 
chorionic gonadotropin [β-hCG]) must be performed before vaccination at Visit 1 (Day 1) in 
WOCBP as described in Section 1.3. Urine or serum tests can be used, and results must be 
negative before vaccination can occur.
8.3.3 Body Temperature Measurement
Each participant's body  temperature must be taken before vaccination as described in 
Section 1.3.
Oral bod y temperatures will also be documented by participants using their eVRC during the 
eVRC -specified postvaccination follow -up period (Section 8.3.4).
For this study , any  oral or ty mpanic temperature ≥100.4°F (≥38.0°C) or axillary  or temporal 
temperature ≥99.4°F (≥37.4°C )will be considered an AE of fever. All fevers must b e 
reported Day 1 through Day 14, unless the fever is a sy mptom of another reported AE. 
  054D4P 
  05KG6X
PRODUCT:   V114  42
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
8.3.4 Safety Assessments and Use of the eVRC
All participants will be observed for at least 30 minutes after each vaccination for an y 
immediate reactions. If any  immediate AEs are observed during this period, the time at which 
the event occurred within this timeframe, as well as the event itself, an y concomitant 
medications that were administered, and resolution of the event must be recorded on the 
appropriate eCRF.
Participant s will use the eVRC (Section 8.1.9) to document the following information:
•Oral bod y temperatures measured Day 1 (day  of vaccination) through Day 5 
postvaccination
•Solicited injection -site AEs (redness/ery thema, swelling, and tenderness/pain) Day 1 
through Day 5 postvaccination
•Solicited sy stemic AEs (muscle pain/my algia, joint pain/arthralgia, headache, and 
tiredness/fatigue) Day 1 through Day 14 postvaccination
•Any other injection -site or sy stemic AEs Day 1 through Day 14 postvaccination
•Concomitant medications and nonstudy  vaccinations Day 1 to Day 14 postvaccination
8.3.5 Clinical Laboratory Assessments
Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency.
•All protocol -required laborator y assessments, as defined in Appendix 2 , must be 
conducted in accordance with the laboratory  manual and the SoA .
•If laboratory  values from nonprotocol -specified laboratory  assessments performed at the 
institution’s local laboratory  require a change in stud y participant management or are 
considered clinically  significant by  the investigator (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SL AB).
•For any laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study , every  attempt should be made to perform repeat assessments 
until the values return to normal or baseline or if a new baseline is established as 
determined b y the investigator .
8.4 Adverse Events (AEs), Serious Adverse Events (SAEs) ,and Other Reportable 
Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causalit y of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other r eportable safet y event reports can be found in Appendix 3 . 
  054D4P 
  05KG6X
PRODUCT:   V114  43
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Adverse events, SAEs, and other reportable safety events will be reported by  the participant 
(or, when appropriate, b y a caregiver, surrogate, or the participant's legall y authorized 
representative ).
The investigator and an y designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safet y events. 
Investigators remain responsible for following up AE s, SAEs, and othe r reportable safety  
events for outcome according to Section 8.4.3 .
The investigator, who is a qualified ph ysician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safet y events with respect to seriousness, 
intensity /toxicity  and causality .
8.4.1 Time Period and Frequency for Collecting AE, SAE ,and Other Reportable 
Safety Event Information
All AEs, SAEs, and other reportable safety events that occur after the consent form is signed 
but before allocation/randomization must b e reported by  the investigator if they  cause the 
participant to be excluded from the study , or are the result of a protocol -specified 
intervention, including but not limited to washout or discontinuation of usual therap y, diet, 
placebo treatment, or a proc edure.
All AEs, SAEs, and other reportable safety events must be reported b y the investigator from 
the day  of allocation/randomization to the first vaccination and from the day of each 
vaccination through 14 day s postvaccination. SAEs must also be reported throughout the 
duration of the individual’s participation in the study, regardless of whether or not related to 
the Sponsor’s product .
Additionally , any SAE brought to the attention of an investigator at an y time outside of the 
time period specified in th e previous paragraph also must be reported immediatel y to the 
Sponsor if the event is either:
1.A death that occurs prior to the participant completing the study .
OR
2.An SAE that is considered by  an investigator who is a qualified ph ysician to be 
vaccine -related .
Investigators are not obligated to activel y seek AE sor SAE sor other reportable safety  events 
in former stud y participants. However, if the investigator learns of an y SAE, including a 
death, at an y time after a participant has been discharged from the study, and he/she 
considers the event to be reasonabl y related to the study intervention or study  participation, 
the investigator must promptly  notify  the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety  events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 3. 
  054D4P 
  05KG6X
PRODUCT:   V114  44
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Table 3 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safet y Events
Type of Event Reporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation 
through 
Protocol -
specified Follow-
up PeriodReporting Time Period:
After the Protocol -
specified Follow- up 
PeriodTime Frame 
to Report 
Event and 
Follow -up 
Inform ation 
to Sponsor:
Nonserious Adverse 
Event (NSAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Not required Per data entry 
guidelines
Serious Adverse Event 
(SAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Report if:
-drug/vaccine related.
-any death until 
participant completion of 
study
(Follow  ongoing to 
outcome)Within 24 
hours of 
learning of 
event
Pregnancy/Lactation 
ExposureReport if:
-due to 
intervention
-causes exclusionReport all Previously reported –
Follow  to 
completion/termination; 
report outcomeWithin 24 
hours of 
learning of 
event
Event of Clinical 
InterestThere are no ECI sfor this study .
Cancer Report if:
-due to 
intervention
-causes exclusionReport all Not required Within 5 
calendar days 
of learning of 
event
Overdose Report if:
-receiving 
placebo run -in or 
other run -in 
medication Report all Not required Within 5 
calendar days 
of learning of 
event
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or SAE sand other 
reportable safet y events. Open -ended and nonleading verbal questioning of the participan t is 
the preferred method to inquire about AE occurrence. 
  054D4P 
  05KG6X
PRODUCT:   V114  45
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts . All AE s, SAE s, and other reportable safet y events ,
including pregnancy  and exposure during breastfeeding , cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3 ). In addition, the investigator will 
make every  attempt to follow all nonserious AEs that occur in randomized participants for 
outcome. Further information on follow -up procedures is given in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by  the investigator to the Sponsor of SAE is essential 
so that legal obligations and ethical responsibilities towards the safet y of participants and the 
safety of a stud y intervention under clinica l investigation are met.
The Sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
Sponsor will comply  wth country -specific regulatory  requirements and global laws and 
regulations relating to safety reporting to regulatory authorities , IRB/IECs, and investigators.
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (SUSAR s) according to local regulatory  requirements and Sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAE) from the Spon sor will file it 
along with the IB and will notify  the IRB/IEC, if appropriate according to local requirements .
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy  and infant exposure during breastfeeding are not considered AEs, an y 
pregnancy  orinfant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occurs during the stud y are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy . 
Pregnancy  outcomes of spontaneous abortion, missed abortion, benign h ydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as 
serious events (Important Medical Events). If the pregnancy c ontinues to term, the outcome 
(health of infant) must also be reported.
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
This is not applicable to this study . 
  054D4P 
  05KG6X
PRODUCT:   V114  46
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
8.4.7 Events of Clinical Interest (ECI s)
There are no events of clinical interest for this study .
8.5 Treatment of Overdose
In this study , an overdose is the administration of more than 1 dose of an y individual study  
vaccine in an y 24-hour period .
No specific information is available on the treatment of overdose .
All reports of overdose must be reported b y the investigator within 5 calendar days to the 
Sponsor either by electronic media or paper. Electronic reporting procedures can be found in 
the electronic data collection (EDC) data entry guidelines. Paper reporting procedures can be 
found in the Investigator Trial File Binder (or equivalent) .
8.6 Pharmacokinetics
PK parameters will not be evaluated in this study .
8.7 Pharmacodynamics
Pharmacod ynamic parameters will not be evaluated in this study .
8.8 Future Biomedical Research S ample Collection
If the participant signs the future biomedical r esearch consent, the following specime ns will 
be obtained as part of future biomedical r esearch:
•DNA for future research
•Leftover stud y serum after completion of immunogenicity testing stored for future 
research
8.9 Medical Resource Utilization and Health Economics
Medical Resource Utilization and Health Economics are not evaluated in this study .
8.10 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure -related details are provided 
inSection 8 .
8.10.1 Screening
Screening procedures will be conducted at Visit 1 (Day 1) as outlined in Section 1.3. 
  054D4P 
  05KG6X
PRODUCT:   V114  47
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
8.10.2 Treatment Period/Vaccination Visit
Requirements during the treatment period are outlined in Section 1.3.
9 STATISTICAL ANALYSIS PLAN
This section outlines the statistical analy sis strategy  and procedures for the study . If, after the 
study  has begun, but prior to any  unblinding/final database lock, changes are made to 
hypotheses, or the statistical methods related to those hy potheses, th en the protocol will be 
amended (consistent with International Council for Harmonisation [ICH]Guideline E -9). 
Changes to other non -confirmatory  anal yses made after the protocol has been finalized, but 
prior to unblinding/final database lock, will be docum ented in a supplemental Statistical 
Analy sis Plan (sSAP) and referenced in the Clinical Study  Report for the study . Post hoc 
exploratory  anal yses will be clearly  identified in the Clinical Study  Report.
9.1 Statistical Analysis Plan Summary
Key elements of th e statistical anal ysis plan are summarized below; the comprehensive plan 
is provided in Section 9.2 to Section 9.12.
Study Design Overview A Phase 3, Multicenter, Randomized, Double -blind, Active 
Com parator -controlled, Lot -to-Lot Consistency Study to Evalu ate the 
Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 
50 Years of Age or Older (PNEU -TRUE)
Treatm entAssignment Participants will be randomly assigned in a 3:3:3:1 ratio into1 of 
4vaccination groups :V114 Lot 1, V114 Lot 2, V114 Lot 3, or 
Prevnar 13™. Randomization will be stratified into 3 groups based on 
the participant’s age (50 to 64 years of age, 65 to 74 years of age, and 
≥75 years of age) at the time of randomization as described in 
Section 6.3.2.
Analysis Populations Immunogenicity : Per -Protocol (PP)
Safety : All Participants as Treated (APaT)
Prim ary Endpoint(s) Immunogenicity :
Serotype -specific OPA GMTs for the 15 serotypes in V114 at 
30 days postvaccination (Day 30)
Safety :
Proportion of participants with solicited injection -site AEs 
(redness/erythema, swelling, and tenderness/pain) from Day 1 
through Day 5postvaccination
Proportion of participants with solicited systemic AEs (muscle 
pain/myalgia, joint pain/arthralgia, headache, and 
tiredness/fatigue) from Day 1 through Day 14postvaccination
Proportion of participants with vaccine -related SAEs from Day 1 
to Month 6 postvaccination
Key Secondary Endpoints Immunogenicity :
Serotype -specific IgG GMCs for the 15 serotypes in V114 at 
30days postvaccination (Day 30) 
  054D4P 
  05KG6X
PRODUCT:   V114  48
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Statistical Methods for Key 
Immunogenicity AnalysesImmunogenicity analyses will be conducted for each of the 
15pneumococcal serotypes in V114.
Each possible pairw ise comparison of lots will be made (Lot 1 to 
Lot2, Lot 1 to Lot 3, and Lot 2 to Lot 3). Each pairw ise comparison of 
lots will consist of two 1-sided tests at the α=0.0 25level. Rejecting the 
null hypothesis of nonequivalence for any test is equivalent to 
requiring the bounds of the 95% CI on the pairwise lot -to-lot 
comparison of the V114 GMT ratio sto be betw een 0.5and 2.0.
Estimation of the serotype -specific OPA GMT rati os and 95% CIs 
will be conducted using the constrained longitudinal data analysis 
(cLDA) method [Liang, K -Y and Zeger, S. L. 2000] .
Statistical Methods for Key 
Safety Analysesp-Values (Tier 1 endpoints) and 95% CIs (Tier 1 and Tier 2 endpoints) 
will be provided for betw een-treatm ent differences in the percentage 
of participants with events; these analyses will be performed using the 
Miettinen and Nurminen (M&N) method [Miettinen, O. and 
Nurminen, M. 1985] .
Interim Analyses To support the periodic review of safety and tolerability data across 
the adult V114 Phase 3 program, an external unblinded statistician 
will provide unblinded interi m safety summaries to an independent 
external DMC for their review. There are no plans to conduct an 
interim analysis of unblinded immunogenicity data in this study. 
How ever, unblinded immunogenicity data will be made available to 
the DMC upon request to e nable a benefit -risk assessment.
Multiplicity The overall success of the study requires demonstrating success on all 
15 pneumococcal serotypes for all 3 pairw ise comparisons for V114 
lotsthatareevaluated in the primary immunogenicity objective. Since 
comparisons are made individually for each of the 15 serotypes and 
for each pairw ise comparison, this approach controls the 2 -sided type I 
error rate at 0.05, and no multiplicity adjustment is required.
No m ultiplicity adjustments will be made for the safety comparisons.
Sample Size and Power This study will randomize approximately 667 participants into each of 
3manufactured lots of V114 (Lot 1, Lot 2, and Lot 3) and 
220participants into the Prevnar 13™ group .
This study has >90% pow er to demonstrate equivalent immunogenicity 
across the 3V114 lots of the OPA GMT ratio for the 15 serotypes
contained in V 114 at an overall α=0.05 (2-sided) level.
9.2 Responsibility for Analyses/In -house Blinding
The statistical anal ysis of the data obtained from this study  will be the responsibility  of the 
Clinical Biostatistics department of the Sponsor. This study  will be conducted as a 
double -blind study  under in -house blinding procedures. The official, final database will not 
be unblinded until m edical/scientific review has been performed, protocol deviations have 
been identified, and data have been declared final and complete.
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for 
study  treatment assignment .Randomization will be implemented in an IRT. Blinding issues 
related to the planned interim anal yses are described in Section 9.7. 
  054D4P 
  05KG6X
PRODUCT:   V114  49
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
9.3 Hypotheses/Estimation
Objectives and h ypotheses of the stud y are stated in Section 3.
9.4 Analysis Endpoints
Immunogenicit y and safety  analy sis endpoints that will be evaluated for within - and/or 
between -intervention differences are listed below.
9.4.1 Immunogenicity Endpoints
The primary  immunogenicity  analy sis endpoints are the serot ype-specific OPA GMTs at 
30days postvaccination (D ay 30).
The secondary  immunogenicity  anal ysis endpoints include:
•Seroty pe-specific IgG GMCs at 30 days postvaccination (Day  30)
•Seroty pe-specific GMFRs and proportions of participants with a ≥4-fold rise from 
prevaccination (Day 1) to 30 day s postvaccinati on (Day  30) for both OPA and IgG 
responses
9.4.2 Safety Endpoints
The safet y analysis endpoints include:
•Proportion of participants with solicited injection -site AEs (redness/ery thema, swelling, 
and tenderness/pain) from Day 1 through Day 5 postvaccination
•Proportion of participants with solicited sy stemic AEs (muscle pain/m yalgia, joint 
pain/arthralgia, headache, and tiredness/fatigue) from Day 1 through Day 14 
postvaccination 
•Proportions of participants with the broad AE categories consisting of an y AEand any
vaccine -related AE from Day  1 through Day  14postvaccination.
•Proportions of participants with the broad AE categories consisting of anySAE, any
vaccine -related SAE , anddeath from Day  1 through the duration of participation in the 
study .Asthis is a single -dose study ,the broad AE category  of discontinuation of study  
intervention due to an AE is not applicable.
•Proportion of participants with maximum temperature measurements meeting the 
Brighton Collaboration cut points from Day  1 through Day  5 pos tvaccination . 
  054D4P 
  05KG6X
PRODUCT:   V114  50
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
9.5 Analysis Populations
9.5.1 Immunogenicity Analysis Populations
The Per -Protocol (PP) population will serve as the primary  population for the anal ysis of 
immunogenicit y data in this study. The PP population consists of all randomized participants 
without deviations from the protocol that may  substantially  affect the results of the 
immunogenicit y endpoint(s). Potential deviations that may result in the exclusion of a 
participant from the PP population for all immunogenicity anal yses include:
•Failure to receive an y study  vaccine at Visit 1 (Day 1)
•Failure to receive correct clinical material as per randomization schedule at Visit 1 
(Day 1) (ie, participants who were cross -treated)
•Receipt of prohibited medication or prohibited vaccine prior to stud y vaccination
Additional potential deviations that may  result in the exclusion of a participant ’s 
measurement from a specific time point assessment in the PP population for immunogenicit y 
analyses include:
•Receipt of prohibited medication or prohibited vacci ne pri or to a blood sample collection
•Collection of blood sample outside of the prespecified window (as described in 
Section 1.3)
The final determination on protocol deviations, and thereby the composition of the PP 
population, will be made prior to the fi nal unblinding of the database. Participants will be 
included in the vaccination group to which they  are randomized for the analy sis of 
immunogenicit y data using the PP population.
A supportive anal ysis using the Full Anal ysis Set (FAS) population will als o be performed 
for the primary  immunogenicity  endpoints. The FAS population consists of all randomized 
participants who received at least 1 vaccination and have at least 1 serology result. 
Participants will be included in the vaccination group to which the y are randomized for the 
analysis of immunogenicity  data using the FAS population.
9.5.2 Safety Analysis Populations
Safety  anal yses will be conducted in the All Participants as Treated (APaT) population, 
which consists of all randomized participants who receive d study  vaccination. Participants 
will be included in the group corresponding to the study  vaccination they  actually  received 
for the analy sis of safet y data using the APaT population. This will be the group to which 
they are randomized except for particip ants who take incorrect stud y vaccination; such 
participants will be included in the treatment group corresponding to the study vaccination 
actuall y received. 
  054D4P 
  05KG6X
PRODUCT:   V114  51
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
At least 1 temperature measurement obtained subsequent to study  intervention is required for 
inclusion i n the analy ses of temperature.
9.6 Statistical Methods
Statistical testing and inference for immunogenicity  and safet y anal yses are described in 
Section 9.6.1 and Section 9.6.2, respectivel y. Unless otherwise stated, all statistical tests will 
be condu cted at the α=0.05 (2 -sided) level. Section 9.6.3 describes how demographic and 
baseline characteristics will be summarized.
9.6.1 Statistical Methods for Immunogenicity Analyses
This section describes the statistical methods that address the primary and secondary  
immunogenicit y objectives.
Immunogenicit y anal yses will be conducted separately  for each of the 15 pneumococcal 
seroty pes across the 3 different lots of V114 (Lot 1, L ot 2, and Lot 3) .
Primary Endpoint /Hypothesis
The primary  objective ( to compare the serot ype-specific OPA G MTs at 30 day s 
postvaccination [ Day 30]across the 3 different lots of V114) will be assessed via the primary  
hypothes is.
Each possible pairwise comparison of lots will be made (Lot 1 to Lot 2, Lot 1 to L ot 3, and 
Lot 2 to Lot 3). Each possible pairwise comparison of lots will consist of two 1-sided testsat 
the α=0. 025level. Rejecting the null hy pothesis of nonequivalence for an y test is equivalent 
to requiring the bounds of the 95% CI on the pairwise lot -to-lot compar ison of the V114 
GMT ratios to be between 0.5and2.0.
For each of the 1 5serot ypes in V114 and for each pairwise comparison , OPA GMTs between 
participants administered different lots of V114 at 30 day s postvaccination will be compared 
via the following equivalence hypotheses:
H0: GMT x/GMT y< 0.5 or GMT x/GMT y> 2.0 versus
H1: 0.5 ≤ GMT X/GMT y≤ 2.0
where GMT xis serot ype-specific OPA GMT for one of the V114 lotsand GMT yis 
seroty pe-specific OPA GMT for another V114 lot . A ratio between 0.5 and 2.0 corresp onds
toensuring that there’s no more than a 2.0-fold difference between OPA GMT sacross any of 
the V114lots(Lot1 vs Lot 2, Lot1 vs Lot 3, and Lot 2 vs Lot 3) . Rejecting the null 
hypothesis ( H0) at the two 1-sided α=0.0 25 level corresponds to the bound sof the 95% CI on 
the GMT ratio between each V114 lot(Lot1/Lot 2, Lot1/Lot 3, and Lot2/Lot 3)being 
between 0.5 and 2.0 and would lead to the conclusion that the OPA response sfor the 
15seroty pes across the V114 lotareequivalent. 
  054D4P 
  05KG6X
PRODUCT:   V114  52
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Estimation of the GMT ratios and 95% CI s, and the hy pothesis test will be conducted using a 
cLDA method proposed by  Liang and Zeger [Liang, K -Y and Zeger, S. L. 2000] utilizing 
data from the participants randomized to V114 . In this model, the response vector consists of 
the log -transformed antibody  titers at baseline (Visit 1 [Day1])and 30 day s postvaccination 
(Visit 2 [Day 30]). The repeated -measures model will include terms for vaccination group 
(V114 Lot1, V114 Lot2,and V114 Lot3), time, the interaction of time -by-vaccination 
group (with a restriction of the same baseline mean across groups), age stratum (ie, 50 to 64 
years, 65 to 74 y ears, and ≥75years) at baseline, and age stratum -by-time interaction. This 
model will allow for different baseline means for each stratum, but restrict the baseline mean 
within the age stratum levels to be the same for all V114 vaccination groups . An unstructured 
covariance matrix will be used to model the correlation among repeated me asurements. The 
Kenward -Roger adjustment will be used with restricted (or residual) maximum likelihood to 
make proper statistical inference. This model allows the inclusion of participants who are 
missing either the baseline or postbaseline measurements, t hereb y increasing efficiency.
Secondary Endpoints
A similar statistical model as used for the primary objective will be used to address the 
secondary  objective that evaluate sthe serot ype-specific IgG GMCs at 30 day s 
postvaccination compared across 3 diffe rent lots of V114 and combined lots of V114 
compared to Prevnar 13™. Given thedisparit y in sample size across the intervention groups
for the combined lots of V114 versus Prevnar 13™comparison ,convergence issues for the 
model are possible due to sensitivity  of the model to differences in covariance structure 
between time points across intervention groups. Details of the methods to be used for this 
analysis if any  of the models fail to converge will be provided in the sSAP.
Descriptive statistics w ith point estimates and within -group 95% CIs will be provided for all 
other immunogenicit y endpoints. For the continuous endpoints, the point estimates will be 
calculated b y exponentiating the estimates of the mean of the natural log values and the 
within -group CIs will be derived by exponentiating the bounds of the CIs of the mean of the 
natural log values based on the t -distribution. For the dichotomous endpoints, the 
within -group CIs will be calculated based on the exact method proposed by Clopper and 
Pearson [CLOPPER, C. J. and PEARSON, E. S. 1934] .
Reverse Cumulative Distribution Curves for both OPA titers and IgG concentrations at 
30days postvaccination with each lotof V114 will be graphic ally displayed by serotype.
A detailed analy sis strategy  for immunogenicity  endpoints is listed in Table 4. 
  054D4P 
  05KG6X
PRODUCT:   V114  53
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Table 4 Analy sis Strategy  for Immunogenicit y Variables
Endpoint/Variable
(Description, Time Point)Prim ary vs. 
Supportive 
Approach†Statistical Method‡ Analysis 
PopulationMissing 
Data 
Approach
Prim ary Endpoint
OPA GMTs at Day 30PcLDA§
(estimate, 95% CI , 
p-value s)PP
Model -based
S FAS
Secondary Endpoint
IgG GMCs at Day 30 PcLDA§
(estimate, 95% CI)PP Model -based
GMFRs and proportion sof participants 
with a ≥4-fold rise from baseline to 
30days postvaccination for both OPA 
and IgG responsesPDescriptive Statistics
(estimate, 95% CI)PPMissing data 
will not be 
imputed
†P = Primary approach; S = Supportive approach.
‡Statistical models are described in further detail below:
§
cLDA model with terms for vaccination group, time, the interaction of time -by-vaccination, age stratum at 
baseline, and age stratum -by-time interaction.
CI = confidence interval ; cLDA = constrained longitudin al data analysis ; FAS = Full Analysis Set; 
GMC =Geom etric Mean Concentration; GMFR = geometric mean fold rise; GMT = Geometric Mean Titer; 
IgG = Immunoglobulin G; OPA= opsonophagocytic activity; PP = Per -Protocol .
9.6.2 Statistical Methods for Safety Analyses
Safety  and tolerability  will be assessed b y clinical review of all relevant parameters ,
including AEs and postvaccin ation temperature measurements.
Consistency  of the safet y profile across lotswill be assessed via p oint estimates and 95% CI s
(for select safety  endpoints) within each of the V114 vaccination group s(Lot 1, Lot 2, Lot 3) . 
Details will be provided in the sSAP. The anal ysis of safet y will then be performed for V114 
overall (combining the Lot 1, L ot 2, and Lot 3 vaccination groups) versus the P revnar 13™ 
vaccination group following a tiered approach as detailed below (Table 5).
The tiers differ with respect to the anal yses that will be performed. AEs (specific terms as 
well as sy stem organ class [SOC] terms) are either pre- specified as “Tier 1” endpoints or will 
be classified as belonging to "Tier 2" or "Tier 3" based on the number of events observed. 
  054D4P 
  05KG6X
PRODUCT:   V114  54
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Tier 1 Events
Safety  parameters or AEs of special interest that are identified a priori constitute “ Tier 1” 
safet y endpoints that will be subject to inferential testing for statistical significance with 
p-values and 95% CI s to be provided for between -treatment differences in the proportion of 
participants with events; these anal yses will be performed usi ng the Miettinen and Nurminen 
(M&N) method [Miettinen, O. and Nurminen, M. 1985] , an unc onditional, asy
mptotic 
method. For this protocol, solicited injection -site AEs (redness/ery thema, swelling, and 
tenderness/ pain) from Day 1 through Day 5 postvaccination and solicited s ystemic AEs 
(muscle pain/my algia, joint pain/arthralgia, headache, and tiredness/fatigue) from Day 1 
through Day 14 postvaccination are considered Tier 1 events.
Tier 2 Events
Tier 2 parameters will be assessed via point estimates with 95% CIs provided for differences 
in the proportion of participants with events (also via the M&N method) [Miettinen, O. and 
Nurminen, M. 1985] .
Membership in Tier 2 requ ires that at least 36 participants in the V114 combined group 
(combin ingLot1, Lot 2, and L ot3 vaccination group s) or 4 participants in the Prevnar 13™
group exhibit the event . Because man y 95% CIs for Tier 2 events may  be provided without
adjustment for multiplicity, the CIs should be regarded as a helpful descriptive measure to be 
used in review, not a formal method for assessing the statistical significance of the 
between -group differences in AEs.
In addition, the broad AE categories con sisting of the proportion of participants with any AE, 
a vaccine -related AE, an SAE, a vaccine -related SAE, and death will be considered Tier 2 
endpoints. Nonserious adverse events (NSAEs) will be followed for 14 days postvaccination
and SAEs will be follo wed for 6 months postvaccinatio n. The proportion of participants with 
maximum temperature measurements meeting the Brighton Collaboration cut points will also 
be considered Tier 2 endpo ints.
Tier 3 Events
Safety  endpoints that are not Tier 1 or 2 events ar e considered Tier 3 events. Only  point 
estimates by  treatment group are provided for Tier 3 safet y parameters. 
  054D4P 
  05KG6X
PRODUCT:   V114  55
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Table 5 Analy sis Strategy for Safety  Parameters
Safety 
Tier Safety Endpoint†p-Value‡95% CI fo r 
Between -Group 
Com parison‡Descriptive
Statistics
Tier 1Injection -siteredness/erythema (Days 1to5) X X X
Injection -site swelling (Days 1to5) X X X
Injection -sitetenderness /pain (Days 1to5) X X X
Muscle pain/myalgia (Days 1 to 14) X X X
Joint pain/arthralgia (Days 1to14) X X X
Headache (Days 1 to14) X X X
Tiredness/fatigue (Days 1to14) X X X
Tier 2Any AE†X X
Any Vaccine -Related AE†X X
Any SAE†X X
Any Vaccine -Related SAE†X X
Death†X X
Maximum temperature measurements meeting 
the Brighton Collabo ration cut points (Days 1 
to 5)X X
Specific AEs by SOC and PT§(incidence 
≥36participants in the combined V114 group 
or ≥4participants in the Prevnar 13™group )X X
Tier 3Specific AEs by SOC and PT§(incidence 
<36participants in the combined V114 group 
and <4 participants in the Prevnar 13™group)X
†These endpoints are broad AE categories. For example, descriptive statistics for the safety endpoint of 
“Any AE” will provide the number and percentage of participants with at least 1AE.
‡These analyses will be performed using the M&N method [Miettinen, O. and Nurminen, M. 1985] .
§Includes only those endpoints not prespecified as Tier 1 or not already prespecified as Tier 2 endpoints.
AE = adverse event; CI = confidence interval; M&N = Miettinen an d Nurminen; PT = pref erred term; 
SAE =serious adverse event; SOC =system organ class; X = results will be provided .
9.6.3 Demographic and Baseline Characteristics and Other Analysis
The comparability  of the vaccination groups for each relevant demographic and baseline 
characteristic will be assessed using summary  tables. No statistical hy pothesis tests will be 
performed on these characteristics. The number and percentage of participan ts randomized
anddiscontinued from thestudy  and discontinuation reasons will be display ed. Demographic 
variables (age, race, and gender), baseline characteristics, the number (%) of subjects 
reporting specific prior medications within 14 days prior to th e first vaccinatio n, the number 
(%) of subjects reporting specific concomitant medications within 14 day s following an y 
vaccination, the number (%) of subjects reporting specific prior vaccinations within 30 days 
prior to the first vaccination, and the num ber (%) of subjects reporting specific concomitant 
vaccinations within 30 days following an y vaccination will be summarized by vaccination 
group either b y descriptive statistics or categorical tables. 
  054D4P 
  05KG6X
PRODUCT:   V114  56
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
9.7 Interim Analyses
A periodic review of safety  and toler ability  data across the V114 Phase 3 adult program will 
be conducted b y an independent, unblinded, external DMC. A description of the structure
andfunction ofthe DMC, along with the timing and content of the safet y review ,will be 
outlined in the DMC cha rter. Information regarding the composition of the DMC is provided 
in Appendix 1. There are no plans to conduct an interim anal ysis of unblinded 
immunogenicit y data in this study . However, unblinded immunogenicit y data will be made 
available to the DMC u pon request to enable a benefit -risk assessment.
The DMC will serve as the primary  reviewer of the results of the ongoing safet y reviews and 
will make recommendations for discontinuation of the study or protocol modifications to an 
executive committee of the Sponsor (see Appendix 1 for details on the Committees Structure 
for this study ). If the DMC recommends modifications to the design of the protocol or 
discontinuation of the study , this Executive Oversight Committee (EOC) of the Sponsor (and 
potentially  other limited Sponsor personnel) may  be unblinded to results at the intervention 
level to act on these recommendations. The extent to wh ich individuals are unblinded with 
respect to ongoing safet y reviews will be documented by  the external unblinded statistician. 
Additional logistical details will be provided in the DMC Charter.
Study  enrollment is likely  to be ongoing at the time of external DMC review. Blinding to 
intervention assignment will be maintained at all investigational sites. Participant -level 
unblinding will be restricted to an external unblinded statistician performi ng ongoing safet y 
review s. Intervention -level ongoing safet y reviews will be provided by  the external 
unblinded statistician to the DMC. Prior to final study unblinding, the external unblinded 
statistician will not be involved in any discussions regarding modifications to the protocol, 
statistical methods, identification of protocol deviations, or data validation efforts after the 
safet y review s.
9.8 Multiplicity
The overall success of the study  requires demonstrating success on all 15 pneumococcal 
seroty pes f or all 3 pairwise comparisons for V114 lots that areevaluated in the primary  
immunogenicit y objective. Since comparisons are made individually for each of the 
15seroty pes and for each pairwise comparison, this approach controls the 2 -sided ty peI 
error r ate at 0.05, and no multiplicity  adjustment is required.
No multiplicity  adjustments will be made for the safet y comparisons.
9.9 Sample Size and Power Calculations
9.9.1 Sample Size and Power for Immunogenicity Analyses
This study  will randomize approximately  667participants to receive each of 3manufactured 
lots of V114 (L ot 1, Lot 2, and L ot 3) and 220 participants to receive Prevnar 13™. 
  054D4P 
  05KG6X
PRODUCT:   V114  57
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
For the primary  hypothesis, this study  has >90% power to demonstrate equivalent 
immunogenicit y across the 3V114 lots. The p ower and sample size are base d on the 
following assumptions:
•90% evaluability  rate (approximately  600 evaluable participants per intervention group)
•The underl ying serot ype-specific OPA GMT ratios for each of the 15 pneumococcal 
seroty pes is 1.0 .
•The varia bilities for OPA titers in the V114 vaccination groups are the same as those 
observed in V114 -006. That is, the standard deviations of the natural log titers for the 
15pneumococcal serot ypes range from 1.33 to 2.24 .
•The statistical criterion for equivalen ce requires the bounds of the 2-sided 95% CI of the 
OPA GMT ratios to be between 0.50 and 2.0 .
9.9.2 Sample Size and Power for Safety Analyses
The probability  of observing at least 1SAE in this study  depends on the number of 
participants vaccinated and the underl ying incidence of participants with an SAE in the study  
population. Calculations below assume that 100% of the randomized participants will be 
evaluable for safet y analyses. T here is an 80% chance of observing at least 1SAE among 
2000 participants in V114 group (Lot 1, Lot 2, Lot 3 combined) if the underly ing incidence 
of an SAE is 0.08% (1 of every  1243 participants receiving the vaccine). There is a 50% 
chance of observing a t least 1SAE among 2000 participants in the V114 group if the 
underly ing incidence of an SAE is 0.03% (1 of every  2885 participants receiving the 
vaccine). If no SAEs are observed among 2000 participants, this study  will provide 97.5% 
confidence that the underly ing percentage of participants with an SAE is <0.18% (1 in every  
542 participants) in the V114 group (Lot 1, Lot 2, Lot 3 combined).
Table 6summarizes the percentage point differences between the 2 vaccination groups that 
could be detected with 80% probability  for a variety  of hypothetical underly ing incidences of 
an AE. 
  054D4P 
  05KG6X
PRODUCT:   V114  58
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Table 6 Differences in the Incidence of Adverse Event Rates Between the 2 Vaccination 
Groups That Can be Detected With an Approximately  80% Probability  
Incidence of Adverse Event Risk Difference
V114 (%)
N=2000Prevnar 13 ™(%)
N=220Percentage Points
1.5 0.1 1.4
5.4 2.0 3.4
9.9 5.0 4.9
16.5 10.0 6.5
22.5 15.0 7.5
28.3 20.0 8.3
39.3 30.0 9.3
The incidences presented here are hypothetical and do not represent actual adverse experiences in either group. 
The incidences assume a 2 -sided 5% alpha level, with sample sizes of 2000 participants in the V114 group 
(Lot 1, Lot 2, Lot 3 combined) and 220 participants in the Prevnar 13 ™group. No multiplicity adjustments 
were made.
The calculations are based on an asymptotic method proposed by Farrington and Manning (1990) [Farrington, 
C. P. 1990] .
9.10 Subgroup Analyses
To determine whether the intervention effect is consistent across various subgroup s, the 
estimate of the between -group treatment effect (with a nominal 95% CI for each V114 
vaccination group ) will be summarized for the primary immunogenicit y endpoint . The 
95% CI will only  be calculated if there aremore than 10 participants in each vaccination 
group for each subgroup. I n addition, a summary of AEs and a summary  of solicited AEs will 
be provided for each subgroup (point estimates only )for V114 overall (combining the Lot 1, 
Lot 2, and Lot 3 vaccination groups) and the Prevnar 13™ vaccination group s. The following 
are examples of classification variables:
•Age category  (50 to 64 years, 65 to 74 y ears, and ≥75 y ears)
•Race (eg, White, Black, Asian, and Other)
•Sex (female, male)
Further details of subgroup analyses will be documented in the sSAP . 
  054D4P 
  05KG6X
PRODUCT:   V114  59
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
9.11 Compliance (Medication Adherence)
Given that participants will receive a single dose of V114 or Prevnar 13™ , compliance will 
not be calculated. However, the number and proportion of randomized participants recei ving 
V114 or Prevnar 13™ will be summarized (Section 9.12).
9.12 Extent of Exposure
The extent of exposure will be summarized by  the number and proportion of randomized 
participants administered V114 or Prevnar 13™. 
  054D4P 
  05KG6X
PRODUCT:   V114  60
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1 Code of Conduct for Clinical Trials
Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc. (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A.Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participant s inclinical trials is the 
overriding concern in the design of clinical trials . In all cases, M SD clinical trials will be conducted in compliance 
with local and/or national regulation s (eg, International Council for Harmonisation Good Clinical Practice [ICH -
GCP]) and in accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B.Scope
Highest ethical and scientific standards shall be endorsed for al l clinical interventional investigations sponsored by 
MSD irrespective of the party (parties) employed for their execution (eg, contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observat ional in nature, or 
which are retrospective. Further, this Code does not apply to investigator -initiated trials , which are not under the 
full control of M SD.
II.Scientific Issues
A.Trial Conduct
1.Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis -driven to assess safety, 
efficacy, and/or pharmacokinetic or pharmacodynamic indices of M SD or comparator products. 
Alternatively, M SDmay conduct outcomes research trials, trials to assess or validate various en dpoint 
measures, or trials to determine patient preferences, etc.
The design (ie, participant population, duration, statistical power) must be adequate to address the specific
purpose of the trial. P articipants must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
MSD selects investigative sites based on medical expertise, access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by M SD personnel to assess the ability to successfully conduct the trial.
3.Site Monitoring/Scientific Integrity
Investigative t rial sites are monitored to assess compliance with the trial protocol and general principles of 
Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data 
are verified versus source documentation according to standard operating procedures. Per MSD policies and 
procedures, if fraud, scientific/research misc onduct, or serious GCP -noncompliance is suspected, the issues  
  054D4P 
  05KG6X
PRODUCT:   V114  61
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
areinvestigated. When necessary, the clinical site will be closed, the responsible regulatory authorities and 
ethics review commi ttees notified.
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the prespecified plans for data analysis. To the 
extent scientifically appropriate, MSDseeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pilot trials are intended to be hypothesis -generating rather 
than hypothesis testing , in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by statistical issues such as multiplicity.
MSD’s policy on authorship is consistent with the re commendations published by the International Committee of 
Medica l Journal Editors (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. M SD funding of a trial will be acknowledged in 
publications.
III.Participant Protection
A. Ethics Committee Review (Institutiona lReview Board [ IRB]/Independent Ethics Committee [ IEC])
All clinical trials will be reviewed an d approved by an IRB/IEC before being initiated at each site. Significant 
changes or revisions to the protocol will be approved by the ethics committee prior to implementation, except 
changes required urgently to protect participant safety that may be enac ted in anticipation of ethics committee 
approval. For each site, the ethics committee and M SDwill approve the par ticipant informed consent form.
B. Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local stand ard of care.
All participation in M SD clinical tria ls is voluntary. Participants enter the trial only after informed consent is 
obtained. Participants may withdraw from a n MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
law, only the investigator, Sponsor (or representative), ethics committee, and/or regulatory authorities will have 
access to confidential medical records t hat might identify the participant by name.
D. Genomic Research
Genomic r esearch will only be conducted in accordance with a protocol and informed consent authorized by an 
ethics c ommittee.
IV. Financial Considerations
A. Pay ments to Investigators
Clinical trials are time -and labor -intensive. It is M SD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of M SD trials. M SD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts. 
  054D4P 
  05KG6X
PRODUCT:   V114  62
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
MSD does not pay for participant referrals. However, M SDmay compensate referrin g physicians for time spent 
on chart review to identify potentially eligible participants.
B.Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by M SDand that the investigator or sponsoring 
institution is being pai d or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from M SDtrials will indicate M SD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by investigators and support staff (eg, to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices .
V. Investigator Commit ment
Investigators will be expected to review M SD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these et hical and scientific standards .
10.1.2 Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54). I t is the 
Sponsor's responsibility  to determine, based on these regulations, whether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.
The investigator/subinvestigator(s) agree, if requested by  the Sponsor in accordance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certificati on/Disclosure Form, commonly  known as a financial disclosure form, provided by  
the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the United States for these purposes. This may involve th e 
transmission of information to countries that do not have laws protecting personal data.
10.1.3 Data Protection
Participants will be assigned a unique identifier by the Sponsor. An y participant records or 
datasets that are transferred to the Sponsor will conta in the identifier only ; participant names 
or an y information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by  the 
Sponsor in accordance with loca l data protection law. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other authori zed personnel appointed by  the S ponsor, by  
appropriate IRB/IEC members, and b y inspectors from regulatory authorities. 
  054D4P 
  05KG6X
PRODUCT:   V114  63
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
10.1.3.1 Confidentiality of Data
By signing this protocol, the investigator affirms to the Sponsor that information furnished to 
the investigator b y the Sponsor will be maintaine d in confidence, and such information will 
be divulged to the IRB, IEC,or similar or expert committee; affiliated institution and 
employ ees, only  under an appropriate understanding of confidentialit y with such board or 
committee, affiliated institution an d employ ees. Data generated b y this study will be 
considered confidential by the investigator, except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
10.1.3.2 Confidentiality of Participant Records
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory  authority  representatives may  consult and/or cop y study  documents to 
verify  worksheet/ CRF data. By  signing the consent form, the participant ag rees to this 
process. If study  documents will be photocopied during the process of verify ing 
worksheet/ CRF information, the participant will be identified b y unique code only; full 
names/initials will be masked prior to transmission to the Sponsor.
By sign ing this protocol, the investigator agrees to treat all participant data used and 
disclosed in connection with this study  in accordance with all applicable privacy  laws, rules 
and regulations.
10.1.3.3 Confidentiality of IRB/IEC Information
The Sponsor is required to record the name and address of each IRB/IEC that reviews and 
approves this study . The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements b y requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies .
10.1.4 Committees Structure
10.1.4.1 Scientific Advisory Committee
This study  was developed in collaboration with a Scientific Advisory  Committee (SAC). The 
SAC is comprise d of both Sponsor and non -Sponsor scientific experts who provide input 
with respect to study  design, interpretation of study  results, and subsequent peer -reviewed 
scientific publications.
10.1.4.2 Executive Oversight Committee
The Executive Over sight Committee (EOC) is comprise d of members of Sponsor Senior 
Management. The EOC will receive and decide upon any  recommendations made by  the
external DMC regarding the study . 
  054D4P 
  05KG6X
PRODUCT:   V114  64
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
10.1.4.3 External D ata Monitoring Committee
To supplement the routine study  monitoring outlined in this protocol, an external DMC will 
monitor the interim data from this study . The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be involved with the study in an y other 
way (eg, they  cannot be stud y investigators) and must have no competing interests that could 
affect their roles with respect to the study .
The DMC will make recommendations to the EOC regarding steps to ensure both participant 
safet y and the continued ethical integrity of the study. Also, the DMC will review interim 
study  results, consider the overall risk and benefit to study  participants ( Section 9.7 I nterim 
Analy sis) and recommend to the EOC whether the study  should continue in accordance with 
the protocol.
Specific details regardi ng composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the study  governance structure; and requirements for and proper documentation 
of DMC repo rts, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by all the DMC members.
10.1.5 Publication Policy
The results of this study  may  be published or presented at scientific meetings. The Sponsor 
will comply  with the requirements for publication of study  results. I n accordance with 
standard editorial and ethical practice, the Sponsor will generall y support publication of 
multicenter studies only  in their entiret y and not as individual site data. I n this case, a 
coordi nating investigator will be designated b y mutual agreement.
If publication activity is not directed b y the Sponsor, the investigator agrees to submit all 
manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect 
propriet ary inform ation and to provide comments.
Authorship will be determined by  mutual agreement and in line with I nternational Committee 
of Medical Journal Editors authorship requirements .
10.1.6 Compliance with Study Registration and Results Posting Requirements
Unde r the terms of the Food and Drug Administration Amendments Act (FDAAA) of 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the study  is solel y responsible for determining whether the stud yand its results are subject
to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study , will 
review this protocol and submit the information necessary  to fulfill these requiremen ts. MSD 
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to identify  potentiall y appropriate studies for their 
disease conditions and pursue participation b y calling a central contact number for further 
information on appropriate study  locations and study  site contact information. 
  054D4P 
  05KG6X
PRODUCT:   V114  65
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
By signing this protocol, the investigator acknowledges that the statutory  obligations under 
FDAAA, the EMA clinical trials directive ,or other locally  mandated registries are that of the 
Sponsor and agrees not to submit any  information about this study  or its results to those 
registries.
10.1.7 Compliance with Law, Audit, and Debarmen t
By signing this protocol, the investigator agrees to condu ct the study  in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of G CP
(eg, International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use G CP: Cons olidated Guideline and other generally 
accepted standards of GCP ); and all applicable federal, state and local laws, rules and 
regulations relating to the conduct of the clinical study .
The Code of Conduct, a collection of goals and considerations that gov ern the ethical and 
scientific conduct of clinical investigations sponsored b y MSD, is provided i n this appendix 
under the Code of Conduct for Clinical Studies.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator b y the Sponsor.
The investigator will promptly  inform the Sponsor of an y regulatory authority inspection 
conducted for this study .
The investigator agr ees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to an y citations resulting 
from regulatory  authority inspection and will provide the Sponsor with a copy  of the 
proposed response for consultation before submission to the regulatory  authority . 
Persons debarred from conducting or working on clinical studies by  any court or regulatory  
authority  will not be allowed to conduct or work on this Sponsor’s studies. The investigat or 
will immediately  disclose in writing to the Sponsor if any  person who is involved in 
conducting the study  is debarred or if any  proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened .
10.1.8 Data Quality Assurance
All participant data relating to the stud y will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verify ing that data entries a re accurate and correct b y 
physicall y or electronically signing the CRF.
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y. 
  054D4P 
  05KG6X
PRODUCT:   V114  66
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
The investigator must maintain accurate documentation (source data) that suppo rts the 
information entered in the CRF.
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents.
Study  documentation will be promptly  and fully  disc losed to the Sponsor by the investigator 
upon request and also shall be made available at the study site upon request for inspection, 
copy ing, review, and audit at reasonable times b y representatives of the Sponsor or an y 
regulatory  authorities. The invest igator agrees to promptly  take an y reasonable steps that are 
requested b y the Sponsor or any regulatory  authorit ies as a result of an audit or inspection to 
cure deficiencies in the stud y documentation and worksheets/CRFs .
The Sponsor or designee is respon sible for the data management of this study  including 
quality  checking of the data.
Study  monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and v erifiable from 
source documents; that the safet y and rights of participants are being protected; and that the 
study  is being conducted in accordance with the currentl y approved protocol and an y other 
study  agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including signed ICF, pertaining to the conduct of this study  must 
be retained b y the investigator for 15 ye ars after study  completion unless local regulations or 
institutional policies require a longer retention perio d. No records may  be destroy ed during 
the retention period without the written approval of the Sponsor. No records may be 
transferred to another location or part y without written notification to the Sponsor .
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. The investigator/institution should maintain adequate and 
accurate source documents and study  records that include al lpertinent ob servations on each 
of the site’s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the original entry, and should be ex plained if necessary  (eg, via 
an audit trail). Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepanci es must be explained. The 
investigator /institution may need to request previous medical records or transfer records, 
depending on the study . Also, current medical records must be available . 
  054D4P 
  05KG6X
PRODUCT:   V114  67
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
10.1.10 Study and Site Closure
The Sponsor or its designee may  stop the study  or study  site participation in the study  for 
medical, safety , regulatory , administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurel y terminates a particular stud y site, the Sponsor wil l 
promptly  notify  that study  site’s IRB/IEC . 
  054D4P 
  05KG6X
PRODUCT:   V114  68
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
10.2 Appendix 2: Clinical Laboratory Tests
•Pregnancy  testing:
-Pregnancy  testing requirements for study  inclusion are described in Section 5.1.
-Additional serum or urine pregnancy  tests may  be performed, as determined
necessary  by the investigator or required b y local regulation, to establish the absence 
of pregnancy  at an y time during the subject's participation in the study. 
  054D4P 
  05KG6X
PRODUCT:   V114  69
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
•An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study  intervention, whether or not considered related to the 
study  intervention.
•NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study intervention.
•NOTE: For purposes of AE definition, study  intervention (also referred to as Sponsor’s 
product) includes an y pharmaceutical product, biological product, vaccine, diagnostic 
agent, or protocol specified procedure whether investigational or marketed (including 
placebo, active comparator product, or run -in intervention) , manufactured by , licensed 
by, provided by , or distributed by  the Sponsor for human use in this study .
Events meeting the AE definition
•Any abnormal laboratory test results (hematology , clinical chemistry, or urinaly sis) or 
other safet y assessments (eg, E CG, radiological scans, vital signs measurements), 
including those that worsen from baseline ,considered clinicall y significant in the medical 
and scientific judgment of the investigator.
•Exacerbation of a chronic or intermittent pre -existing condition inc luding either an 
increase in frequency  and/or intensity  of the condition.
•New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
•Signs, sy mptoms, or the clinical sequ elae of a suspected drug -drug interaction.
•Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication.
•For all reports of overdose (whether accidental or intentional) with an associated AE, th e 
AE term should reflect the clinical s ymptoms or abnormal test result. An overdose 
without any  associated clinical sy mptoms or abnormal laboratory  results is reported using 
the terminology  “accidental or intentional overdose without adverse effect.”
•Any new cancer or progression of existing cancer. 
  054D4P 
  05KG6X
PRODUCT:   V114  70
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Events NOT meeting the AE d efinition
•Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
•Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study  that do not worsen.
•Surgery  planned prior to informed consent to treat a pre -existing condition that has not 
worsened.
•Refe r to Section 8.4.6 for protocol -specific exceptions.
10.3.2 Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met.
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
•The term “ life-threatening ”in the definition of “serious ”refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
•Hospitalization is defined as an inpatient admission, regardless of length of stay, even 
if the hospitalization is a precautionary  measure for continued observation. (Note: 
Hospitalization for an elective procedure to treat a pre -existing c ondition that has not 
worsened is not an SAE. A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history .
d.Results in persistent or significant disability/inca pacity
•The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions. 
  054D4P 
  05KG6X
PRODUCT:   V114  71
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
•This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiti ng, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
•In offspring of participant taking the produ ct regardless of time to diagnosis.
f.Other important medical events
•Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or hospitalization but may 
jeopardize the participant or may require medical or surgical intervention to prevent 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug dependency 
or drug a buse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
•Is a cancer
•Is associated with an overdose
10.3.4 Recording AE and SAE
AE and SAE r ecording
•When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory , and diagnostics reports) related to 
the event.
•The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
•It is not acceptable for the investigator to send photocopies of the participant’s medical 
records to the Sponsor in lieu of completion of the AE C RF page. 
  054D4P 
  05KG6X
PRODUCT:   V114  72
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
•There may  be instances when copies of medical records for certain cases are requested b y 
the Sponsor. I n this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copies of the medical records be fore submission to the 
Sponsor.
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. I n such cases, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE/ SAE.
Assessment of i ntensity /toxicity
•An event is defined as “serious ”when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
•The investigator will make an assessment of intensity  for each AE and SAE (and other 
reportable safet y event) reported during the stud y and assign it to 1 of the following 
categories: 
-Mild: An event that is easily  tolerated b y the participant, causing minimal discomfort 
and not interfering with every day activiti es (for pediatric studies, awareness of 
symptoms, but easily  tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
every day activities (for pediatric studies definitel y acting like something is wrong).
-Severe: An event t hat prevents normal every day activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category  utilized for rating 
the intensity  of an event; and both AE and SAE can be assessed as severe (for 
pediatric studies, extremel y distressed or unable to do usual activities).
•Injection site ery thema/redness or swelling from the day  of vaccination through Day  5 
postvaccination will be evaluated b y maximum size.
•The investigator will make an assessment of toxicity for each AE and SAE (and other 
reportable event) reported during the study. A toxicity grade will be assigned to 
injection -site AEs, specific sy stemic AEs, other s ystemic AEs, and vital sign 
(temperature) AEs as shown in the following tables. The toxicity  grading scales u sed in 
this study  are adapted from the “FDA Guidance for Industry : Toxicity  Grading Scale for 
Health y Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, 
September 2007.” 
  054D4P 
  05KG6X
PRODUCT:   V114  73
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
•Injection -Site AE Toxicity Grading Scale
Injection Site 
Reaction to Study 
Vaccine/PlaceboaGrade 1 Grade 2 Grade 3 Grade 4
Injection -site AEs occurring Days 1 through 5 following receipt of study vaccine/placebo
Pain/Tenderness Does not interfere 
with activityRepeated use of 
non-narcotic pain 
reliever >24 hours 
or interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospitalization
Erythema/Redness Size measured as
BSize measured as
C or DSize measured as
E→Necrosis or 
exfoliative 
dermatitis or 
results in ER visit 
or hospitalization
Induration/Swelling Size measured as 
BSize measured as
C or DSize measured as
E→Necrosis or ER 
visit or 
hospitalization
Other Does not interfere 
with activityRepeated use of 
non-narcotic pain 
reliever >24 hours 
or interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospitalization
Any injection -site reaction that begins ≥6 days after receipt of study vaccine/placebo
Pain/tenderness
Erythema/Redness
Induration/Swelling
OtherDoes not interfere 
with activityRepeated use of 
non-narcotic pain 
reliever >24 hours 
or interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospitalization
Abbreviations: AE = adverse event; ER = emergency room; eVRC = electronic Vaccine Report Card .
aBased upon information provided by the participant on the eVRC and verbally during VRC review. Erythema/Redness 
and Induration/Swelling are specific injection -site AEs with size designations of lette rs A through E →, based upon a 
graphic in the eVRC. Size A is not assigned a toxicity grade; however, injection -site AEs that measure size A should be 
reported as adverse experiences. If the participant has an ER visit or is hospitalized for any injection -site AE, that AE is to 
be assigned a toxicity grade of 4, regardless of the size measured. 
  054D4P 
  05KG6X
PRODUCT:   V114  74
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Specific Systemic AE Toxicity Grading Scale
Systemic (General)Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Headache No interference 
with activityRepeated use of non -
narcotic pain reliever 
>24hours or some 
interference with 
activitySignificant; any use 
of narcotic pain 
reliever or prevents 
daily activityER visit or 
hospitalization
Fatigue No interference 
with activitySome interference 
with activitySignificant; 
prevents daily 
activityER visit or 
hospitalization
Myalgia No interference 
with activitySome interference 
with activitySignificant; 
prevents daily 
activityER visit or 
hospitalization
Abbreviations: AE = adverse event; ER = emergency room .
Other Systemic AE Toxicity Grading Scale
Systemic IllnessaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)b
Illness or clinical AE 
(as defined 
according to 
applicable 
regulations)No interference 
with activitySome interference 
with activity not 
requiring medical 
interventionPrevents daily 
activity and 
required medical 
interventionER visit or 
hospitalization
Abbreviations: AE = adverse event; ER = emergency room; eVRC = electronic Vaccine Report Card; SAE = serious 
adverse event .
aBased upon information provided by the patient on the eVRC and verbally during the eVRC review during the primary 
safety follow -up period. For SAEs reported beyond the pr imary safety follow -up period, grading will be based upon the 
initial report and/or follow -up of the event.
bAEs resulting in death will be assessed as Grade 4.
Vital Sign (Temperature) Toxicity Grading Scale
Vital SignsaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Fever (°C)b
(°F)b38.0 to 38.4
100.4 to 101.138.5 to 38.9
101.2 to 102.039.0 to 40.0
102.1 to 104.0>40.0
>104.0
aParticipant should be at rest for all vital sign requirements.
bOral temperature; no recent hot or cold beverages or smoking. 
  054D4P 
  05KG6X
PRODUCT:   V114  75
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Assessment of c ausality
•Did the Sponsor’s product cause the AE?
•The determination of the likelihood that the Sponsor’s product caused the AE will be 
provided b y an investigator who is a quali fied ph ysician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causalit y noted on the AE 
form, ensures that a medically  qualified assessment of causalit y was done. This initialled 
document must be retained fo r the required regulatory  time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following c omponents are to be used to assess the relationship between the 
Sponsor’s product and the AE; the greater the correlation with the components and 
their respective elements (in number and/or intensity ), the more likel y the Sponsor’s 
product caused the AE:
-Exposure: Is there evidence that the participant was actuall y exposed to the 
Sponsor’s product such as: reliable history, acceptable compliance assessment (diary, 
etc.), seroconversion or identification of vaccine virus in bodily  specimen?
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor’s product? I s the time of onset of the AE compatible 
with a vaccine -induced effect?
-Likely Cause: Is the AE not reasonabl y explained by  another etiology  such as 
underly ing disease, other drug(s)/vaccine(s), or other host or environmental factors?
-Rechallenge: Was the participant re -exposed to the Sponsor’s product in the study ?
-If yes, did the AE recur or worsen?
-If yes, this is a positive rechallenge.
-If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent 
disability , or (2) the study  is a single -dose vaccine study ; or (3) Sponsor’s product(s) is/are 
used only  1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERI OUS AND 
MAY HAVE BEEN CAUSED BY THE SPONSOR’S PRODUCT, OR I F RE -EXPOSURE 
TO THE SPONSOR’S PRODUCT POSES ADDITIONAL POTENTIAL SI GNIFICANT 
RISK TO THE PARTI CIPANT THEN THE RECHALLENGE MUST BE APPROVED I N 
ADVANCE BY THE SPONSOR CLINICAL DIRECTOR, AND IF REQUI RED, THE 
IRB/IEC. 
  054D4P 
  05KG6X
PRODUCT:   V114  76
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
-Consistency with study intervention profile: Is the clinical/pathological 
presentation of the AE consistent with previous knowledge regarding the Sponsor’s 
product or drug class pharmacology  or toxicology?
-The assessment of relationship will be reported on the CRFs/worksheets b y an 
investigator who is a qualified phy sician according to his/her best clinical judgment, 
including consideration of the above elements.
-Use the following scale of criteria as guidan ce (not all criteria must be present to be 
indicative of a Sponsor’s product relationship).
-Yes, there is a reasonable possibility  of Sponsor’s product relationship:
-There is evidence of exposure to the Sponsor’s product. The temporal sequence of 
the AE on set relative to the administration of the Sponsor’s product is reasonable. 
The AE is more likely explained by the Sponsor’s product than b y another cause.
-No, there is not a reasonable possibility  of Sponsor’s product relationship:
-Participant did not rece ive the Sponsor’s product OR temporal sequence of the 
AE onset relative to administration of the Sponsor’s product is not reasonable OR 
the AE is more likely  explained by  another cause than the Sponsor’s product. 
(Also entered for a participant with overdo se without an associated AE.)
•For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
•There may  be situations in which an SAE has occurred and the investigator ha s minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causalit y for every event before the 
initial transmission of the SAE data to the Sponsor.
•The investigat or may  change his/her opinion of causality  in light of follow -up 
information and send an SAE follow -up report with the updated causality  assessment.
•The causality  assessment is 1 of the criteria used when determining regulatory  reporting 
requirements.
Follow-up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested b y Sponsor to 
elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This may  
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
•New or updated information will be recorded in the CRF. 
  054D4P 
  05KG6X
PRODUCT:   V114  77
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
•The investigator will submit any  updat ed SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.5 Reporting of AE s, SAE s, and Other Reportable Safety Events to the Sponsor
AE, SAE, and other reportable safety event reporting to Sponsor via electronic data 
collection tool
•The pri mary  mechanism for reporting to the Sponsor will be the electronic data collection 
(EDC) tool.
•Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
•If the electronic s ystem is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
•Reference Section 8.4.1 for reporting time requirements.
•The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
•After the stud y is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry  of new data or changes to existing data.
•If a site receives a report of a new SAE from a study  participant or receives updated data 
on a previousl y reported SAE after the EDC tool has been taken off -line, th en the site can 
report this information on a paper SAE form or by telephone (see next section).
•Contacts for SAE reporting can be found in the Investigator Stud y File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
•In rare circumstances and in the absence of facsimile equipment, notification by  
telephone is accept able with a cop y of the SAE data collection tool sent by overnight 
mail or courier service.
•Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames .
•Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study  File Binder (or equivalent) . 
  054D4P 
  05KG6X
PRODUCT:   V114  78
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
10.4 Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definition s, Collection, and Documentation
Not applicable. 
  054D4P 
  05KG6X
PRODUCT:   V114  79
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
10.5 Appendix 5: Contraceptiv e Guidance
10.5.1 Definitions
Women of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below):
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the following:
- Documented h ysterectomy
-Documented bilateral salpingectomy
-Documented bilateral oophorectom y
For individuals with permanent infertility  due to an alternate medical cause other than the 
above (eg, Mullerian agen esis, androgen insensitivity ), investigator discretion should be 
applied to determining study  entry .
Note: Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.
•Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.
◦A high follicle stimulating hormone (FSH) level in the postmenopausal range may 
be used to confirm a postmenopausal state in women not usin g hormonal 
contraception or hormone replacement therap y (HRT). However, in the absence 
of 12 months of amenorrhea, confirmation with two FSH measurements in the 
postmenopausal range is required.
-Females on HRT and whose menopausal status is in doubt will be required to use one 
of the nonhormonal highly effective contraception methods if they wish to continue 
their HRT during the study . Otherwise, they  must discontinue HRT to allow 
confirmation of postmenopausal status before study  enrollment. 
  054D4P 
  05KG6X
PRODUCT:   V114  80
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
10.5.2 Contraception Requirements
Female Participants
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependencyb
Failure rate of <1% per year when used consistently and correctl y.
•Progestogen -only contraceptive implantc
•Intrauterine hormone -releasing system (IUS)c(IUS is a progestin -releasing IUD)
•Intrauterine device (IUD)
•Bilateral tubal occlusion
•Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual 
partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly 
effective method of contraception should be used. A spermatogenesis cycle is approximately 90 days.
Note: Docum entation of azoospermia can come from the site personnel’s revie w of the participant’s 
medical records, medical examination, or medical history intervie w.
Highly Effective Contraceptive Methods That Are User Dependentb
Failure rate of <1% per year when us ed consistently and correctly.
•Com bined (estrogen -and progestogen -containing) hormonal contraception
-Oral
-Intravaginal
-Transdermal
-Injectable
•Progestogen -only hormonal contraception
-Oral
-Injectable
Sexual Abstinence
•Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated w ith the study intervention. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the 
preferred and usual lifestyle of the participant.
Acceptable Contraceptive Methods
Failure rate of >1% per year when used consistently and correctly.
•Progesterone -only hormonal contraception where inhibition of ovulation is not the primary mode of 
action
•Male or female condom with or without spermicide
•Cervical cap, diaphragm, or sponge with spermicide
•A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide 
(double barrier methods)d
a.Contraceptive use by men or women should be consistent with local regulations regarding the use of 
contraceptive methods for participants of clinical studies.
b.Typical use failure rates are higher than perfect -use failure rates (ie, when used consistently and correctly).
c.If locally r equired, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable 
contraceptive implants are limited to those which inhibit ovulation
d.A combination of male condom with either cap, diaphragm, or sponge with spermicide are considere d 
acceptable, but not highly effective, birth control methods.
Note: The follow ing are not acceptable methods of contraception:
-Periodic abstinence (calendar, symp tothermal, post -ovulation methods), withdraw al (coitus interruptus), 
spermicides only, and lactational amenorrhea method (LAM).
-Male and female condom should not be used together (due to risk of failure with friction). 
  054D4P 
  05KG6X
PRODUCT:   V114  81
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
10.5.3 Pregnancy Testing
WOCBP should only  be included after a negative highl y sensitive urine or serum pregnancy 
test.
Pregnancy  testing will be performed whenever an expected menstrual cy cle is missed or 
when pregnancy  is otherwise expected. 
  054D4P 
  05KG6X
PRODUCT:   V114  82
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1. Definitions
a.Biomarker: A biological molecule found in blood, other bod y fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease. A biomarker may be 
used to see how well the body  responds to a treatment for a disease or condition .1
b.Pharmacogenomics: The investigation of variat ions of DNA and RNA characteristics as 
related to drug/vaccine response.2
c.Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on drug/vaccine response.2
d.DNA: Deox yribonucleic acid.
e.RNA: Ribonucleic acid.
2. Scope of Future Biomedical Research
The specimens consented and/or collected in this study  as outlined in Section 8.8 will be 
used in various experiments to understand:
◦The biology  of how drugs/vaccines work
◦Biomarkers responsible for how a drug/vaccine enters and is removed by the body
◦Other pathway s drugs/vaccines may  interact with
◦The biology  of disease
The specimen(s) may  be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information ob tained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately  
improve public health through development o f novel treatments targeted to populations 
with the greatest need. All specimens will be used by the Sponsor or those working for or 
with the Sponsor.
3. Summary of Procedures for Future Biomedical Research.
a.Participants for Enrollment
All participants enroll ed in the clinical study  will be considered for enrollment in the 
future biomedical research substudy 
  054D4P 
  05KG6X
PRODUCT:   V114  83
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
b.Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all participa nts or legal guardians, at a 
study  visit by  the investigator or his or her d esignate. Informed consent for future 
biomedical r esearch should be presented to the participants on the visit designated in 
the SoA. If delay ed, present consent at next possible P articipant Visit. Consent forms 
signed b y the participant will be kept at the clinical study site under secure storage for 
regulatory  reasons.
A template of each stud y site’s approved informed consent will be stored in the 
Sponsor’s clinical document repos itory .
c.eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical research will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified 
will be destroy ed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical r esearch will be performed as outlined 
in the SoA. I n general, if additional blood specimens are being collected for future 
biomedical r esearch, these will usually  be obtaine d at a time when the participant is 
having blood drawn for other study  purposes.
4. Confidential Participant Information for Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
specimens, it is critical to link participant' clinical information with future test results. I n 
fact little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like gender, ag e, medical history  and intervention outcomes are 
critical to understanding clinical context of anal ytical results.
To maintain privacy  of information collect ed from specimens obtained for future 
biomedical r esearch, th e Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
At the clinical study  site, unique codes will be placed on the future biomedical r esearch 
specimens. This code is a random number which does not contain an y personally 
identify ing information embedded within it. The link (or key ) between participant 
identifiers and this unique code will be held at the study  site. No personal identifiers will 
appear on the specimen tube. 
  054D4P 
  05KG6X
PRODUCT:   V114  84
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
5. Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for anal yses using good scientific 
practices. Anal yses utilizing the future biomedical r esearch specimens may  be performed 
by the Sponsor, or an additional third party  (eg, a univ ersity  investigator) designated by 
the Sponsor. The investigator conducting the anal ysis will follow the Sponsor’s privacy 
and confidentialit y requirements. An y contracted third part y anal yses will conform to the 
specific scope o f anal ysis outlined in this substudy . Future biomedical r esearch 
specimens remaining with the third part y after specific anal ysis is performed will be 
reported to the Sponsor.
6. Withdrawal From Future Biomedical Research
Participants may withdraw their consent for future biomedical r esearch and ask that thei r 
biospecimens not be used for future biomedical r esearch. Participants may withdraw 
consent at an y time b y contacting the investigator for the main study. If medical records 
for the main study are still available, the investigator will contact the Sponsor using the 
designated mailbox (clinical.specimen.management@merck.com). Subsequently, the 
participant's specimens will be flagged in the biorepository and restricted to main study 
use only . If specimens were collected from study participants specifically for future 
biomedical r esearch, these specimens will be removed from the biorepository and 
destroy ed. Documentation will be sent to the investigator confirming withdrawal and/or 
destruction, if applicable. I t is the responsibility  ofthe investigator to inform the 
participant of completion of the withdrawal and/or destruction, if applicable. Any 
analyses in progress at the time of request for withdrawal/destruction or alread y 
performed prior to the request being received b y the Sponso r will continue to be used as 
part of the overall research study  data and results. No new analy ses would be generated 
after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator i s no longer required by regulatory authorities to retain the main study 
records) or the specimens have been completel y anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situation, 
the req uest for withdrawal of consent and/or destruction cannot be processed.
7. Retention of Specimens
Future biomedical r esearch specimens will be stored in the biorepository  for potential 
analysis for up to 20 y ears from the end of the main study . Specimens may  be stored for 
longer if a regulatory  or governmental authorit y has active questions that are being 
answered. In this special circumstance, specimens will be stored until these questions 
have been adequatel y addressed.
Specimens from the study  site will be s hipped to a central laboratory  and then shipped to 
the Sponsor -designated biorepository . If a central laboratory  is not utilized in a particular 
study , the stud y site will ship directly to the Sponsor -designated biorepository . The 
specimens will be stored under strict supervision in a limited access facility which  
  054D4P 
  05KG6X
PRODUCT:   V114  85
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
operates to assure the integrity of the specimens. Specimens will be destroy ed according 
to Sponsor policies and procedures and this destruction will be documented in the 
biorepository  database.
8. Data Security
Databases containing specimen information and test results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highl y sec ure, and is 
accomplished using network securit y policies and practices based on international 
standards to protect against unauthorized access.
9. Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory  laboratory studies will be reported to the 
participant, famil y, or physicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability , and concerns regarding misinte rpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapidly  report this information to doctors and participants. Parti cipants will not be 
identified by  name in any published reports about this study  or in any  other scientific 
publication or presentation.
10. Future Biomedical Research Study Population
Every  effort will be made to recruit all participants diagnosed and treated on Sponsor 
clinical studies for f uture biomedical r esearch.
11. Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been mini mized and are 
described in the future biomedical r esearch informed conse nt.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy  concerns. Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality . In this highl y unlikely  situation, there is risk that the 
information, like all medical information, may  be misused.
12. Questions
Any questions related to the future biomedical research should be e mailed directly  to 
clinical.specimen.management@merck.com. 
  054D4P 
  05KG6X
PRODUCT:   V114  86
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
13. References
1. National Cancer Institute [I nternet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=45618
2. International Conference on Harmonization [Internet] : E15 : Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data a nd Sample 
Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy /efficacy -single/article/definitions -for-
genomic -biomarkers -pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html 
3. Industry  Pharmacogenomics Working Group [Internet]: Understanding the I ntent, 
Scope and Public Health Benefits of Exploratory  Biomarker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Available at http://i -pwg.org/ 
4. Industry  Pharmacogenomics Working Group [Internet]: Pharma cogenomics 
Informational Brochure for I RBs/IECs and Investigational Site Staff. Available at 
http://i -pwg.org/ 
  054D4P 
  05KG6X
PRODUCT:   V114  87
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
10.7 Appendix 7: Country -specific Requirements
Not applicable. 
  054D4P 
  05KG6X
PRODUCT:   V114  88
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
10.8 Appendix 8: Abbreviations
Abbreviation Expanded Term
AE adverse event
APaT All Participants as Treated
β-hCG beta human chorionic gonadotropin
CAPiTA Community Acquired Pneumonia Immunization Trial in Adults
CFR Codeof Federal Regulations
CI confidence interval
cLDA constrained longitudinal data analysis
CRF Case Report Form
DMC Data Monitoring Committee
DNA deoxyribonucleic acid
ECG electrocardiogram
ECI event of clinical interest
ECL electrochemiluminescence
eCRF electronic Case Report Form
EDC electronic data collection
EMA European Medicines Agency
EOC Executive Oversight Committee
eVRC electronic Vaccination Report Card
FAS Full Analysis Set
FDAAA Food and Drug Administration Amendments Act
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GMC geometric mean concentration
GMFR geometric mean fold rise
GMT geometric mean titer
HIV human immunodeficiency virus
HRT hormone replacement therapy
IB Investigat or’s Brochure
ICF Informe d Consent Form
ICH International Council for Harmonization
IEC Independent Ethics Committee
IgG immunoglobulin G
IM intramuscular
IMP investigational medicinal product
IND Investigational New Drug
IPD invasive pneumococcal disease
IRB Institutional Review Board
IRT interactive response technology
IUD intrauterine device
IUS intrauterine hormone -releasing system
M&N Miettinen and Nurminen
MOPA multiplexed opsonophagocytic assay
MSD Merck Sharp & Dohme Corp.
NIMP non-investigational medicinal product
NSAE nonserious adverse event
OPA opsonophagocytic activity
PCV pneumococcal conjugate vaccine
PK pharmacokinetic
PnECL pneumococcal electrochemiluminescence 
  054D4P 
  05KG6X
PRODUCT:   V114  89
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
Abbreviation Expanded Term
PP Per-Protocol
PT preferred term
RNA ribonucleic acid
SAC Scientific Advisory Committee
SAE serious adverse event
SLAB supplemental laboratory test
SoA schedule of activities
SOC system organ class
sSAP supplemental statistical analysis plan
SUSAR suspected unexpected serious adverse reaction
US United States
WOCBP woman/ women of childbearing potential 
  054D4P 
  05KG6X
PRODUCT:   V114  90
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
11 REFERENCES
[Anttila, M., et al 1999] Anttila M, Voutilainen M, Jäntti V, Eskola J , 
Käyhty H. Contribution of serot ype-specific IgG 
concentration, IgG subclasses and relative antibody  
avidity  to opsonophagocy tic activity  against 
Streptococcus pneumoniae. Clin Exp I mmunol 
1999;118(3):402 -7.03QY70
[Bonten, M. J., et al 2015] Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, 
Patterson S, Gault S, et al. Poly saccharide conjugate 
vaccine against pneumococcal pneumonia in adults. 
N Engl J Med. 2015 Mar 19;372(12):1114 -25.04NFHD
[Burton, Robert L . and Nahm, 
Moon H. 2006]Burton RL, Nahm MH. Dev elopment and validation 
of a fourfold multiplexed opsonization assay  
(MOPA4) for pneumococcal antibodies. Clin 
Vaccine Immunol 2006;13(9):1004 -9.03QT2R
[Centers for Disease Control 
and Prevention 2008]Centers for Disease Control and Prevention (CDC). 
Invasive pneumococcal disease in children 5 y ears 
after conjugate vaccine introduction -eight 
states,1998 -2005. MMWR Morb Mortal Wkly  Rep. 
2008 Feb 15;57(6):144 -8.04KW8S
[Centers for Disease Control 
and Prevention 2010]Centers for Disease Control and Preve ntion. 
Prevention of Pneumococcal Disease Among 
Infants and Children -Use of 13 -Valent 
Pneumococcal Conjugate Vaccine and 23 -Valent 
Pneumococcal Pol ysaccharide Vaccine; 
Recommendations of the Advisory  Committee on 
Immunization Practices (ACI P). MMWR 
2010;59(RR -11):1 -19.03RSB6
[Centers for Disease Control 
and Prevention 2015]Centers for Disease Control and Prevention. 
Epidemiology  and prevention of vaccine -
preventable diseases. 13th ed. Hamborsk y J, Kroger 
A, Wolfe S, editors. Washington (DC): Department
of Health and Human Services (HHS); c2015. 
Chapter 6, Vaccine administration; p. 79 -106.0508PV
[CLOPPER, C. J. and 
PEARSON, E. S. 1934]CLOPPER CJ, PEARSON ES. The use of 
confidence of fiducial limits illustrated in the case 
of the binomial. Biometrika 1934;26(4):404 -13.03RRVC 
  054D4P 
  05KG6X
PRODUCT:   V114  91
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
[Drijkoningen, J. J 2014] Drijkoningen JJ, Rohde GG. Pneumococcal 
infection in adults: burden of disease. Clin 
Microbiol I nfect. 2014 May ;20 Suppl 5:45 -51.04NFHN
[European Centre for Disease 
Prevention and Control 2016]Europea n Centre for Disease Prevention and 
Control. Annual Epidemiological Report 2016 –
Invasive pneumococcal disease. [I nternet]. 
Stockholm: ECDC; 2016. Available from: 
http://ecdc.europa.eu/en/healthtopics/pneumococcal
_infection/Pages/Annual -epidemiological -report-
2016.aspx.04LP3M
[Farrell, D. J, et al 2007] Farrell DJ, Klugman KP, Pichichero M. Increased 
antimicrobial resistance among nonvaccine 
seroty pes of Streptococcus pneumoniae in the 
pediatric population after the introduction of 7 -
valent pneumococcal vaccine in the United States. 
Pediatr Infect Dis J. 2007 Feb;26(2):123 -8.04KWD9
[Farrington, C. P. 1990] Farrington CP, Manning G. Test Statistics and 
Sample Size Formulae for Comparative Binomial 
Trials with Null Hypothesis of Non -Zero Risk 
Difference o r Non -Unity  Relative Risk. Stat Med 
Vol. 9,1447 -1454 (1990)04FS6L
[Guevara, M., et al 2016] Guevara M, Barricarte A, Torroba L, Herranz M, 
Gil-Setas A, Gil F, et al. Direct, indirect and total 
effects of 13- valent pneumococcal conjugate 
vaccination on invasive pneumococcal disease in 
children in Navarra, Spain, 2001 to 2014: cohort 
and case -control stud y. Euro Surveill. 2016;21(14).04KSQ3
[Jokinen, J., et al 2015] Jokinen J, Rinta -Kokko H, Siira L , Palmu AA, 
Virtanen MJ, Nohy nek H, et al. I mpact of te n-valent 
pneumococcal conjugate vaccination on invasive 
pneumococcal disease in Finnish children a 
population -based study . PLoS One. 2015 Mar 
17;10(3):e0120290.04KW7F
[Kobay ashi, M., et al 2015] Kobay ashi M, Bennett NM, Gierke R, Almendares 
O, Moore MR, Whitney  CG, et al. Intervals 
Between PCV13 and PPSV23 Vaccines: 
Recommendations of the Advisory  Committee on 
Immunization Practices (ACI P). MMWR Morb 
Mortal Wkly  Rep. 2015 Sep 4;64(34):944 -7.04P7L H 
  054D4P 
  05KG6X
PRODUCT:   V114  92
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
[Lepoutre, A., et al 2015] Lepoutre A, Varon E, Georges S, Dorleans F, Janoir 
C, Gutmann L , et al. I mpact of the pneumococcal 
conjugate vaccines on invasive pneumococcal 
disease in France, 2001 -2012. Vaccine. 2015 Jan 
3;33(2):359 -66.04KW88
[Lexau, C. A., et al 2005] Lexau CA, Ly nfield R, Danila R, Pilishvili T, 
Facklam R, Farley  MM, et al. Changing 
epidemiology  of invasive pneumococcal disease 
among older adults in the era of pediatric 
pneumococcal conjugate vaccine. JAMA 
2005;294(16):2043 -51.03RBPW
[Liang, K -Y and Zeger, S. L . 
2000]Liang K -Y, Zeger SL. Lon gitudinal data anal ysis of 
continuous and discrete responses for pre -post 
designs. Sank yha: The Indian Journal of Statistics 
2000;62(Series B, Part 1):134 -48.00V5V6
[Martinelli, D., et al 2014] Martinelli D, Pedalino B, Cappelli MG, Caputi G, 
Sallustio A, Fortunato F, et al Towards the 13 -
valent pneumococcal conjugate universal 
vaccination: effectiveness in the transition era 
between PCV7 and PCV13 in I taly, 2010 -2013. 
Hum Vaccin Immunother. 2014;10(1):33 -9.04KW8B
[Metlay , J. P., et al 2006] Metlay  JP,Fishman NO, Joffe M, Edelstein PH. 
Impact of pediatric vaccination with pneumococcal 
conjugate vaccine on the risk of bacteremic 
pneumococcal pneumonia in adults. Vaccine 
2006;24:468 -75.03RC46
[Miettinen, O. and Nurminen, 
M. 1985]Miettinen O, Nurminen M. Comparative Anal ysis 
of Two Rates. Stat Med 1985;4:213 -26.03QCDT
[Moore, M. R., et al 2015] Moore MR, L ink-Gelles R, Schaffner W, Ly nfield 
R, Lexau C, Bennett NM, et al. Effect of use of 13 -
valent pneumococcal conjugate vaccine in children 
on invasive pneumococcal disease in children and 
adults in the USA: analy sis of multisite, population -
based surveillance. Lancet I nfect Dis. 2015 Feb 3. 
[Epub ahead of print].043MRP 
  054D4P 
  05KG6X
PRODUCT:   V114  93
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
[Palmu, A. A., et al 2015] Palmu AA, Kilpi TM, Rinta -Kokko H, Noh ynek H, 
Toropainen M, Nuorti JP, et al. Pneumococcal 
conjugate vaccine and clinically suspected invasive 
pneumococcal disease. Pediatrics. 2015 
Jul;136(1):e22 -7.04KVRL
[Pilishvili, Tamara, et al 
2010]Pilishvili T, Lexau C, Farley MM, Hadler J, 
Harrison LH, Bennett NM, et al. Sustained 
reductions in invasive pneumococcal disease in the 
era of conjugate vaccine. J I nfect Dis 
2010;201(1):32 -41.03R5S4
[Romero -Steiner, S., et al 
1997]Romero -Steiner S, L ibutti D, Pais LB, Dy kes J, 
Anderson P, Whitin JC, et al. Standardizatio n of an 
opsonophagocy tic assay  for the measurement of 
functional antibody  activity  against streptococcus 
pneumoniae using differentiated HL -60 cells. Clin 
Diagn Lab Immunol 1997;4(4):415 -22.03NWQ5
[Ruckinger, S., et al 2009] Ruckinger S, van der Linden M , Reinert RR, von 
Kries R, Burckhardt F, Siedler A. Reduction in the 
incidence of invasive pneumococcal disease after 
general vaccination with 7 -valent pneumococcal 
conjugate vaccine in Germany . Vaccine 
2009;27:4136 -41.03QYQQ
[Tomczy k, S., et al 2014] Tomczy k S, Bennett NM, Stoecker C, Gierke R, 
Moore MR, Whitney  CG, et al. Use of 13 -valent 
pneumococcal conjugate vaccine and 23 -valent 
pneumococcal poly saccharide vaccine among adults 
aged is greater than or equal to 65 y ears: 
recommendations of the Advisor y Committee on 
Immunization Practices (ACI P). MMWR Morb 
Mortal Wkly  Rep. 2014 Sep 19;63(37):822 -5.040XNF
[U.S. Food and Drug 
Administration 2009]U.S. Food and Drug Administration (CDER, CBER, 
CDRH). Guidance for industry  patient -reported 
outcome measure s: use in medical product 
development to support labeling claims [I nternet]. 
Washington: U.S. Department of Health and Human 
Services; 2009. Available from: 
https://www.fda.gov/downloads/drugs/guidances/uc
m193282.pdf04MG9J 
  054D4P 
  05KG6X
PRODUCT:   V114  94
PROTOCOL/AMENDMENT N O.:  020-00  
V114 -020-00 FI NAL PROTOCOL 09-JAN-2019
[Wagenvoort, G. H., et al 
2016]Wagenvoort GH, Knol MJ, de Melker HE, 
Vlaminckx BJ, van der Ende A, Rozenbaum  MH, 
et al.  Risk and outcomes of invasive pneumococcal 
disease in adults with underlying conditions in the 
post-PCV7 era, The Netherlands. Vaccine. 2016 Jan 
12;34(3):334 -40.04KTDB
[Waight, P. A., et al 2015] Waight PA, Andrews NJ, L adhani SN, Sheppard 
CL, Slack MP, Miller E. Effect of the 13 -valent 
pneumococcal conjugate vaccine on invasive 
pneumococcal disease in England and Wales 4 
years after its introduction: an observatio nal cohort 
study . Lancet Infect Dis. 2015 May ;15(5):535 -43.04KTF2
[Weiss, S., et al 2015] Weiss S, Falkenhorst G, van der Linden M, Imohl 
M, von Kries R. I mpact of 10 -  and 13- valent 
pneumococcal conjugate vaccines on incidence of 
invasive pneumococcal d isease in children aged 
under 16 years in Germany, 2009 to 2012. Euro 
Surveill. 2015 Mar 12;20(10):21057.04KTFC
[Whitney , Cynthia G., et al 
2003]Whitney  CG, Farley  MM, Hadler J, Harrison LH, 
Bennett NM, Lynfield R, et al. Decline in invasive 
pneumococca l disease after the introduction of 
protein -polysaccharide conjugate vaccine. N Engl J 
Med 2003;348(18):1737 -46.03QT0D 
  054D4P 
  05KG6X